<SEC-DOCUMENT>0001493152-23-006000.txt : 20230224
<SEC-HEADER>0001493152-23-006000.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224162143
ACCESSION NUMBER:		0001493152-23-006000
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230224
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanara MedTech Inc.
		CENTRAL INDEX KEY:			0000714256
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				592220004
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39678
		FILM NUMBER:		23667670

	BUSINESS ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102
		BUSINESS PHONE:		817-529-2300

	MAIL ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WOUND MANAGEMENT TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20080611

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MB SOFTWARE CORP
		DATE OF NAME CHANGE:	19960805

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INAV TRAVEL CORPORATION
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:SMTI="http://sanaramedtech.com/20230224">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_SMTI_sanaramedtech.com_20230224 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20230224_20230224 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000714256 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityCentralIndexKey">0000714256</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="smti-20230224.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-02-24to2023-02-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-24</xbrli:startDate>
        <xbrli:endDate>2023-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">UNITED
STATES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">SECURITIES
AND EXCHANGE COMMISSION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 40%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">FORM
<span id="xdx_904_edei--DocumentType_c20230224__20230224_zfZeSEeo9gEl"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:DocumentType">8-K</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span id="xdx_90A_edei--DocumentPeriodEndDate_c20230224__20230224_znPy2it39ETf"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 24, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20230224__20230224_zA4mVDIOCCz4"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityRegistrantName">SANARA
    MEDTECH INC.</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
    name of registrant as specified in its charter)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20230224__20230224_zFjfJcYfscKg"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Texas</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityFileNumber_c20230224__20230224_zAvewhWu0oO7"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityFileNumber">001-39678</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20230224__20230224_zRaKGSJqjPil"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityTaxIdentificationNumber">59-2219994</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20230224__20230224_zdLYveN2zy7g"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressAddressLine1">1200
                                            Summit Avenue</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20230224__20230224_ze2Z6F4zY2of"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressAddressLine2">Suite 414</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20230224__20230224_zMpS7loU3A57"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressCityOrTown">Fort
    Worth</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20230224__20230224_zQWhx6glMVYb"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20230224__20230224_z3g7mpvNePci"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressPostalZipCode">76102</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_908_edei--CityAreaCode_c20230224__20230224_zjNA3PmVAhE4"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:CityAreaCode">(817)</ix:nonNumeric></span> <span id="xdx_90C_edei--LocalPhoneNumber_c20230224__20230224_zP3xJkLLB253"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:LocalPhoneNumber">529-2300</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not
Applicable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--WrittenCommunications_c20230224__20230224_zVrLuhNoV7u3"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20230224__20230224_zi1oeJgiu5hf"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementTenderOffer_c20230224__20230224_znkbU5PEL9T"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20230224__20230224_zCZ4Q3TFcaWl"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 20%"><b>Trading
    Symbol(s)</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20230224__20230224_z3iq3ojR2aH6"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:Security12bTitle">Common
    Stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20230224__20230224_zMKXxpQPXk5c"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:TradingSymbol">SMTI</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_907_edei--SecurityExchangeName_c20230224__20230224_zO9lTwL8OAbe"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_908_edei--EntityEmergingGrowthCompany_c20230224__20230224_zOt3kMBOOIUe"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2023, Sanara MedTech Inc., a Texas corporation (the &#8220;Company&#8221;), entered into a Controlled Equity Offering<sup>SM
</sup>Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co., as sales agent (&#8220;Cantor&#8221;), pursuant
to which the Company may offer and sell from time to time, to or through Cantor, shares of the Company&#8217;s common stock, par value
$0.001 per share, having an aggregate offering price of up to $75,000,000 (the &#8220;Shares&#8221;). The offer and sale of the Shares
has been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to the Company&#8217;s
Registration Statement on Form S-3 (File No. 333-251652), which was originally filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on December 23, 2020 and declared effective by the SEC on January 4, 2021 (the &#8220;Registration Statement&#8221;), the base prospectus
contained within the Registration Statement and a prospectus supplement that was filed with the SEC on February 24, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the Shares, if any, pursuant to Sales Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined
in Rule 415(a)(4) promulgated under the Securities Act. Upon delivery of a placement notice and subject to the terms and conditions of
the Sales Agreement, Cantor agreed to use commercially reasonable efforts consistent with its normal trading and sales practices, applicable
state and federal law, rules and regulations and the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon
the Company&#8217;s instructions, including any price, time period or size limits specified by the Company. The Company has no obligation
to sell any of the Shares under the Sales Agreement and may at any time suspend or terminate the offering of its common stock pursuant
to the Sales Agreement upon notice to Cantor and subject to other conditions. Cantor&#8217;s obligations to sell the Shares under the
Sales Agreement are subject to satisfaction of certain conditions, including customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Pursuant
to the Sales Agreement, the Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds from each sale of the Shares,
and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The offering of the Shares pursuant
to the Sales Agreement will terminate upon the termination of the Sales Agreement by Cantor or the Company, as permitted therein.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there
be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or other jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the opinion of Haynes and Boone, LLP relating to the validity of the Shares that may be sold pursuant to the Sales Agreement
is filed herewith as Exhibit 5.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales
Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated February 24, 2023, by and between Sanara MedTech Inc. and Cantor Fitzgerald &amp; Co. </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Haynes and Boone, LLP. </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Weaver and Tidwell, L.L.P.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Haynes and Boone, LLP (included in Exhibit 5.1).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted
exhibit or schedule will be furnished supplementally to the SEC or its staff upon request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 24, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sanara
    MedTech Inc</b>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael D. McNeil</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    D. McNeil</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUqNKHxMSiILEYlet5xiSXdkdq38pP6yVYmGCzPDnTNXiIlIaKsqZDiv8xQKrJtKWoQcb8ior+gu4t0+AtdzvCtjWWo7rD8wJsegYxbTYHlxxnD6VAbLCPxwFjrN3RD5K8gOwuv9mPRNlaitkhVIXULG1LBCK7kbPxTyTZrqbog6IRtFOoJg6o/2B0I/COFIT/kifhhI01h4k6E8kTC1TR/TGks1bCqsXZYZ0b+8Lxi2SUo= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sanara
MedTech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(par
value $0.001 per share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Controlled
Equity Offering<SUP>SM</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Sales
Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
24, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">499
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
MedTech Inc., a Texas corporation (the &ldquo;<B><U>Company</U></B>&rdquo;), confirms its agreement (this &ldquo;<B><U>Agreement</U></B>&rdquo;)
with Cantor Fitzgerald &amp; Co. (the &ldquo;<B><U>Agent</U></B>&rdquo;), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Issuance and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject
to the conditions set forth herein, it may issue and sell to or through the Agent, as sales agent or principal, shares of common stock
(the &ldquo;<B><U>Placement Shares</U></B>&rdquo;) of the Company, par value $0.001 per share (the &ldquo;<B><U>Common Stock</U></B>&rdquo;);
<I>provided</I>, <I>however</I>, that in no event shall the Company issue or sell through the Agent such number or dollar amount of Placement
Shares that would (a) exceed the number or dollar amount of shares of Common Stock registered on the effective Registration Statement
(defined below) pursuant to which the offering is being made, (b) exceed the number of authorized but unissued shares of Common Stock
(less shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise
reserved from the Company&rsquo;s authorized capital stock), (c) exceed the number or dollar amount of shares of Common Stock permitted
to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable) or (d) exceed the number or dollar amount of shares
of Common Stock for which the Company has filed a Prospectus Supplement (defined below) (the lesser of (a), (b), (c) and (d), the &ldquo;<B><U>Maximum
Amount</U></B>&rdquo;). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the
limitations set forth in this <U>Section 1</U> on the amount of Placement Shares issued and sold under this Agreement shall be the sole
responsibility of the Company and that the Agent shall have no obligation in connection with such compliance; <I>provided</I> that the
Agent follows the trading instructions provided by the Company pursuant to any Placement Notice in all material respects. The offer and
sale of Placement Shares through the Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company
and declared effective by the Securities and Exchange Commission (the &ldquo;<B><U>Commission</U></B>&rdquo;) on January 4, 2021, although
nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended (the &ldquo;<B><U>Securities Act</U></B>&rdquo;),
and the rules and regulations thereunder (the &ldquo;<B><U>Securities Act Regulations</U></B>&rdquo;), with the Commission a registration
statement on Form S-3 (File No. 333-251652), including a base prospectus, relating to certain securities, including the Placement Shares
to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file
in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><U>Exchange Act</U></B>&rdquo;),
and the rules and regulations thereunder. The Company has prepared a prospectus or a prospectus supplement to the base prospectus included
as part of the registration statement, which prospectus or prospectus supplement relates to the Placement Shares to be issued from time
to time by the Company (the &ldquo;<B><U>Prospectus Supplement</U></B>&rdquo;). The Company will furnish to the Agent, for use by the
Agent, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating
to the Placement Shares to be issued from time to time by the Company. Except where the context otherwise requires, such registration
statement(s), including all documents filed as part thereof or incorporated by reference therein, and including any information contained
in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act Regulations
or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act Regulations, and any one or more additional
effective registration statements on Form S-3 from time to time that will contain a base prospectus and related prospectus or prospectus
supplement, if applicable (which shall be a Prospectus Supplement), with respect to the Placement Shares, is herein called the &ldquo;<B><U>Registration
Statement</U></B>.&rdquo; The base prospectus or base prospectuses, including all documents incorporated therein by reference, included
in the Registration Statement, as it may be supplemented, if necessary, by the Prospectus Supplement, in the form in which such prospectus
or prospectuses and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b)
under the Securities Act Regulations, together with the then issued Issuer Free Writing Prospectus(es) (as defined below), is herein
called the &ldquo;<B><U>Prospectus</U></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference herein to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall
be deemed to refer to and include the documents, if any, incorporated by reference therein (the &ldquo;<B><U>Incorporated Documents</U></B>&rdquo;),
including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference
herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement,
any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include the filing of
any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the date of the Prospectus
Supplement, Prospectus or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference. For purposes
of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed
to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval system, or
if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &ldquo;<B><U>EDGAR</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Placements</U>. Each time that the Company wishes and determines in its sole discretion to issue and sell Placement Shares hereunder
(each, a &ldquo;<B><U>Placement</U></B>&rdquo;), it will notify the Agent by email notice (or other method mutually agreed to by the
parties) of the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation
on the number of Placement Shares that may be sold in any one day and any minimum price below which sales may not be made (a &ldquo;<B><U>Placement
Notice</U></B>&rdquo;), the form of which is attached hereto as <U>Schedule 1</U>. The Placement Notice shall originate from any of the
individuals from the Company set forth on <U>Schedule 3</U> (with a copy to each of the other individuals from the Company listed on
such schedule) and shall be addressed to each of the individuals from the Agent set forth on <U>Schedule 3</U>, as such <U>Schedule 3
</U>may be amended from time to time. The Placement Notice shall be effective immediately upon receipt by the Agent unless and until
(i) the Agent declines in writing (including by email correspondence to each of the individuals of the other party set forth on <U>Schedule
3</U>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via
auto-reply) to accept the terms contained therein for any reason, in its sole discretion, in which case the Agent shall, within two (2)
Trading Days (as defined below) of the receipt of such Placement Notice, notify the Company (by e-mail notice or other method mutually
agreed to by the parties), (ii) the entire amount of the Placement Shares thereunder have been sold, (iii) the Company suspends or terminates
the Placement Notice or (iv) this Agreement has been terminated under the provisions of <U>Section 12</U>. The amount of any discount,
commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement Shares shall be
calculated in accordance with the terms set forth in <U>Schedule 2</U>. It is expressly acknowledged and agreed that neither the Company
nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers
a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then
only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement
Notice, the terms of the Placement Notice will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Sale of Placement Shares by the Agent</U>. Subject to the provisions of <U>Section 5(a)</U>, the Agent, for the period specified in
the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable
state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market (the &ldquo;<B><U>Exchange</U></B>&rdquo;),
to sell the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The
Agent will provide written confirmation to the Company no later than the opening of the Trading Day immediately following the Trading
Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation
payable by the Company to the Agent pursuant to <U>Section 2</U> with respect to such sales, and the Net Proceeds (as defined below)
payable to the Company, with an itemization of the deductions made by the Agent (as set forth in <U>Section 5(b)</U>) from the gross
proceeds that it receives from such sales. Subject to the terms of the Placement Notice, the Agent may sell Placement Shares by any method
permitted by law deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) of the Securities Act Regulations.
&ldquo;<B><U>Trading Day</U></B>&rdquo; means any day on which Common Stock is traded on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Suspension of Sales</U>. The Company or the Agent may, upon notice to the other party in writing (including by email correspondence
to each of the individuals of the other party set forth on <U>Schedule 3</U>, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
facsimile transmission or email correspondence to each of the individuals of the other party set forth on <U>Schedule 3</U>), suspend
any sale of Placement Shares (a &ldquo;<B><U>Suspension</U></B>&rdquo;); <I>provided</I>, <I>however</I>, that such Suspension shall
not affect or impair any party&rsquo;s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice.
While a Suspension is in effect any obligation under <U>Sections 7(l)</U>, <U>7(m)</U>, and <U>7(n)</U> with respect to the delivery
of certificates, opinions, or comfort letters to the Agent, shall be waived. Each of the parties agrees that no such notice under this
<U>Section 4</U> shall be effective against any other party unless it is made to one of the individuals named on <U>Schedule 3</U> hereto,
as such Schedule may be amended from time to time. Notwithstanding any other provision of this Agreement, during any period in which
the Company is in possession of material non-public information, the Company and the Agent agree that (i) no sale of Placement Shares
will take place, (ii) the Company shall not request the sale of any Placement Shares, and (iii) the Agent shall not be obligated to sell
or offer to sell any Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Sale and Delivery to the Agent; Settlement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Sale of Placement Shares</U><I>.</I> On the basis of the representations and warranties herein contained and subject to the terms
and conditions herein set forth, upon the Agent&rsquo;s acceptance of the terms of a Placement Notice, and unless the sale of the Placement
Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, the Agent,
for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and
sales practices and applicable law and regulations to sell such Placement Shares up to the amount specified, and otherwise in accordance
with the terms of such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be
successful in selling Placement Shares, (ii) the Agent will incur no liability or obligation to the Company or any other person or entity
if it does not sell Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts consistent
with its normal trading and sales practices and applicable law and regulations to sell such Placement Shares as required under this Agreement
and (iii) the Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except
as otherwise agreed by the Agent and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Settlement of Placement Shares</U>. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement
Shares will occur on the second (2nd) Trading Day (or such earlier day as is industry practice for regular-way trading) following the
date on which such sales are made (each, a &ldquo;<B><U>Settlement Date</U></B>&rdquo;). The Agent shall notify the Company of each sale
of Placement Shares no later than the opening of the Trading Day immediately following the Trading Day on which it has made sales of
Placement Shares hereunder. The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement
Shares sold (the &ldquo;<B><U>Net Proceeds</U></B>&rdquo;) will be equal to the aggregate sales price received by the Agent for such
Placement Shares, after deduction for (i) the Agent&rsquo;s commission, discount or other compensation for such sales payable by the
Company pursuant to <U>Section 2</U> hereof, and (ii) any transaction fees imposed by any Governmental Authority in respect of such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Delivery of Placement Shares</U>. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
transfer the Placement Shares being sold by crediting the Agent&rsquo;s or its designee&rsquo;s account (provided the Agent shall have
given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company
through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties
hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement Date,
the Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the Settlement
Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver Placement
Shares on a Settlement Date, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in <U>Section
10(a)</U> hereto, the Company will (i) hold the Agent harmless against any loss, claim, damage, or expense (including reasonable and
documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent
(if applicable) and (ii) pay to the Agent any commission, discount, or other compensation to which it would otherwise have been entitled
absent such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Denominations; Registration</U>. Certificates for the Placement Shares, if any, shall be in such denominations and registered in such
names as the Agent may request in writing at least one full Business Day (as defined below) before the applicable Settlement Date. The
certificates for the Placement Shares, if any, will be made available by the Company for examination and packaging by the Agent in The
City of New York not later than noon (New York time) on the Business Day prior to the applicable Settlement Date. Notwithstanding the
foregoing, the Agent shall not request the issuance of stock certificates in any event for so long as the Company issues shares of Common
Stock in book entry form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Limitations on Offering Size</U>. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares
if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant to
this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount and
(B) the amount authorized from time to time to be issued and sold under this Agreement by the Company&rsquo;s board of directors, a duly
authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances shall
the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price
authorized from time to time by the Company&rsquo;s board of directors, a duly authorized committee thereof or a duly authorized executive
committee. Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Placement Shares sold pursuant
to this Agreement to exceed the Maximum Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to, and agrees with the Agent that as of the
date of this Agreement and as of each Applicable Time (as defined below), unless such representation, warranty or agreement expressly
specifies a different time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement and Prospectus</U>. The Company and the transactions contemplated by this Agreement meet the requirements for
and comply with the applicable conditions set forth in Form S-3 (including General Instructions I.A and I.B) under the Securities Act.
The Registration Statement has been filed with the Commission and has been declared effective by the Commission under the Securities
Act. The Prospectus Supplement will name the Agent as the agent in the section titled &ldquo;Plan of Distribution.&rdquo; The Company
has not received, and has no notice of, any order of the Commission preventing or suspending the use of the Registration Statement, or
threatening or instituting proceedings for that purpose. The Registration Statement and the offer and sale of Placement Shares as contemplated
hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said Rule. Any statutes, regulations,
contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits
to the Registration Statement have been so described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments
or supplements and all documents incorporated by reference therein that were filed with the Commission on or prior to the date of this
Agreement have been delivered, or are available through EDGAR, to the Agent and its counsel. The Company has not distributed and, prior
to the later to occur of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering
material in connection with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus and
any Issuer Free Writing Prospectus to which the Agent has consented (such consent not to be unreasonably withheld, conditioned or delayed).
The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is currently listed on the Exchange under the trading
symbol &ldquo;SMTI.&rdquo; The Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act, delisting the Common Stock from the Exchange, nor has the Company received any notification
that the Commission or the Exchange is contemplating terminating such registration or listing. To the Company&rsquo;s knowledge, it is
in compliance with all applicable listing requirements of the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>No Misstatement or Omission</U>. The Registration Statement, when it became or becomes effective, and the Prospectus, and any amendment
or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects
with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date,
will conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes
effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement thereto, on the date
thereof and at each Applicable Time (defined below), did not or will not include an untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The
documents incorporated by reference in the Prospectus or any Prospectus Supplement did not, and any further documents filed and incorporated
by reference therein will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material
fact required to be stated in such document or necessary to make the statements in such document, in light of the circumstances under
which they were made, not misleading. The foregoing shall not apply to statements in, or omissions from, any such document made in reliance
upon, and in conformity with, information furnished to the Company by the Agent in writing specifically for use in the preparation thereof,
it being understood and agreed that the only such information furnished by the Agent to the Company consists of &ldquo;Agent Information&rdquo;
as defined below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Conformity with the Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus
or any amendment or supplement thereto, and the documents incorporated by reference in the Registration Statement, the Prospectus or
any amendment or supplement thereto, when such documents were or are filed with the Commission under the Securities Act or the Exchange
Act or became or become effective under the Securities Act, as the case may be, conformed or will conform in all material respects with
the requirements of the Securities Act and the Exchange Act, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Financial Information</U>. The consolidated financial statements of the Company included or incorporated by reference in the Registration
Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, together with the related notes and schedules, present fairly,
in all material respects, the consolidated financial position of the Company and its Subsidiaries (as defined below) as of the dates
indicated and the consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the periods
specified and have been prepared in compliance with the requirements of the Securities Act and Exchange Act and in conformity with U.S.
Generally Accepted Accounting Principles (&ldquo;<B><U>GAAP</U></B>&rdquo;) applied on a consistent basis during the periods involved;
there are no financial statements (historical or pro forma) that are required to be included or incorporated by reference in the Registration
Statement and the Prospectus that are not included or incorporated by reference as required; the Company and its Subsidiaries do not
have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), not described or incorporated
by reference in the Registration Statement (excluding the exhibits thereto) and the Prospectus; and all disclosures contained or incorporated
by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, regarding &ldquo;non-GAAP
financial measures&rdquo; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange
Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The interactive data in eXtensible Business Reporting
Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called
for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Conformity with EDGAR Filing</U>. The Prospectus delivered to the Agent for use in connection with the sale of the Placement Shares
pursuant to this Agreement will be identical to the version of the Prospectus created to be transmitted to the Commission for filing
via EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Organization</U>. The Company and each of its significant subsidiaries (as defined in Rule 1-02(w) of Regulation S-X under the Securities
Act) (&ldquo;<B><U>Subsidiaries</U></B>&rdquo;) are duly organized, validly existing as a corporation or other entity and in good standing
under the Laws (as defined below) of their respective jurisdictions of organization. The Company and each of its Subsidiaries are duly
licensed or qualified as a foreign corporation for transaction of business and in good standing under the Laws of each other jurisdiction
in which their respective ownership or lease of property or the conduct of their respective businesses requires such license or qualification,
and have all corporate or other organizational power and authority necessary to own or hold their respective properties and to conduct
their respective businesses as described in the Registration Statement and the Prospectus, except where the failure to be so qualified
or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would
reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition
(financial or otherwise), prospects, stockholders&rsquo; equity or results of operations of the Company and its Subsidiaries taken as
a whole, or prevent or materially interfere with the consummation of the transactions contemplated hereby (a &ldquo;<B><U>Material Adverse
Effect</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Subsidiaries</U>. Except as set forth in the Registration Statement and the Prospectus, the Company owns, directly or indirectly,
all of the equity interests of its Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal
or other restriction, and all the equity interests of its Subsidiaries are validly issued and are fully paid, nonassessable and free
of preemptive and similar rights. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company,
from making any other distribution on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such
Subsidiary from the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>No Violation or Default</U>. Neither the Company nor any of its Subsidiaries is (i) in violation of its certificate of formation or
bylaws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would
constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage,
deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which
the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries are
subject; or (iii) in violation of any Law of any Governmental Authority (as defined below), except, in the case of each of clauses (ii)
and (iii) above, for any such violation or default that would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. To the Company&rsquo;s knowledge, no other party under any material contract or other agreement to which it
or any of its Subsidiaries is a party is in default in any respect thereunder where such default would reasonably be expected to have
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>No Material Adverse Effect</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Prospectus and the Free Writing Prospectuses, if any (including any document deemed incorporated by reference therein), there has
not been (i) any Material Adverse Effect or the occurrence of any development that the Company reasonably expects will result in a Material
Adverse Effect, (ii) any transaction which is material to the Company and its Subsidiaries taken as a whole, (iii) any obligation or
liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or any Subsidiary, which is material
to the Company and its Subsidiaries taken as a whole, (iv) any material change in the capital stock or outstanding long-term indebtedness
of the Company or any of its Subsidiaries or (v) any dividend or distribution of any kind declared, paid or made on the capital stock
of the Company or any Subsidiary, other than in each case above in the ordinary course of business or as otherwise disclosed in the Registration
Statement or Prospectus (including any document deemed incorporated by reference therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Capitalization</U>. The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and
nonassessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights,
rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration
Statement and the Prospectus as of the dates referred to therein (other than the grant of additional options under the Company&rsquo;s
existing stock option plans, changes in the number of outstanding shares of Common Stock of the Company due to the issuance of shares
upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof or forfeitures
of restricted stock) and such authorized capital stock conforms in all material respects to the description thereof set forth in the
Registration Statement and the Prospectus. The description of the securities of the Company in the Registration Statement and the Prospectus
is complete and accurate in all material respects. Except as disclosed in or contemplated by the Registration Statement or the Prospectus,
as of the date referred to therein, the Company does not have outstanding any options to purchase, or any rights or warrants to subscribe
for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares
of capital stock or other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Authorization; Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform
the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal,
valid and binding agreement of the Company enforceable against the Company in accordance with its terms, except to the extent that enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo; rights generally and
by general equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Authorization of Placement Shares</U>. The Placement Shares, when issued and delivered pursuant to the terms contained in the applicable
Placement Notice, which has been approved by the board of directors of the Company or a duly authorized committee thereof, or a duly
authorized executive committee, against payment therefor as provided herein, will be duly and validly issued, fully paid and nonassessable,
free and clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory or contractual preemptive
rights, resale rights, rights of first refusal or other similar rights, and will be registered pursuant to Section 12 of the Exchange
Act. The Placement Shares, when issued, will conform in all material respects to the description thereof set forth in or incorporated
into the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>No Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any Governmental Authority
is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale by the Company of the
Placement Shares, except for such consents, approvals, authorizations, orders and registrations or qualifications as may be required
under applicable state securities Laws or Laws of the Financial Industry Regulatory Authority Inc. (&ldquo;<B><U>FINRA</U></B>&rdquo;)
or the Exchange in connection with the sale of the Placement Shares by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>No Preferential Rights</U>. Except as set forth in the Registration Statement and the Prospectus, (i) no person, as such term is defined
in Rule 1-02 of Regulation S-X promulgated under the Securities Act (each, a &ldquo;<B><U>Person</U></B>&rdquo;), has the right, contractual
or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other capital stock or other securities
of the Company, (ii) no Person has any preemptive rights, resale rights, rights of first refusal, rights of co-sale, or any other rights
(whether pursuant to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common Stock or shares of any other capital
stock or other securities of the Company, (iii) no Person has the right to act as an underwriter or as a financial advisor to the Company
in connection with the offer and sale of the Common Stock, and (iv) no Person has the right, contractual or otherwise, to require the
Company to register under the Securities Act any Common Stock or shares of any other capital stock or other securities of the Company,
or to include any such shares or other securities in the Registration Statement or the offering contemplated thereby, whether as a result
of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated thereby or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Independent Public Accounting Firm</U>. Weaver and Tidwell, L.L.P. (the &ldquo;<B><U>Accountant</U></B>&rdquo;), whose report on the
consolidated financial statements of the Company is filed with the Commission as part of the Company&rsquo;s most recent Annual Report
on Form 10-K filed with the Commission and incorporated by reference into the Registration Statement and the Prospectus, are and, during
the periods covered by their report, were an independent registered public accounting firm within the meaning of the Securities Act and
the Public Company Accounting Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not in violation of
the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<B><U>Sarbanes-Oxley Act</U></B>&rdquo;) with respect
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Enforceability of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus (other
than such agreements that have expired by their terms or whose termination is disclosed in documents filed by the Company on EDGAR) are
legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent that
(i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo; rights
generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited by federal
or state securities Laws or public policy considerations in respect thereof, except for any unenforceability that, individually or in
the aggregate, would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>No Litigation</U>. Except as set forth in the Registration Statement or the Prospectus, there are no actions, suits or proceedings
by or before any Governmental Authority pending, nor, to the Company&rsquo;s knowledge, any audits or investigations by or before any
Governmental Authority, to which the Company or a Subsidiary is a party or to which any property of the Company or any of its Subsidiaries
is the subject that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect and, to the Company&rsquo;s
knowledge, no such actions, suits, proceedings, audits or investigations are threatened or contemplated by any Governmental Authority
or threatened by others; and (i) there are no current or pending audits, investigations, actions, suits or proceedings by or before any
Governmental Authority that are required under the Securities Act to be described in the Prospectus that are not so described; and (ii)
there are no contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement
that are not so filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Compliance with Health Care Laws</U>. The Company has operated and currently is in compliance with all applicable health care laws,
rules and regulations (except where such failure to operate or non-compliance would not, singly or in the aggregate, result in a Material
Adverse Effect), including, without limitation, (i) the Federal, Food, Drug and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.); (ii)
all applicable federal, state, local and all applicable foreign healthcare related fraud and abuse laws, including, without limitation,
the federal Anti-kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the U.S. Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h),
the civil False Claims Act (31 U.S.C. &sect;&sect; 3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal
laws relating to healthcare fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, the healthcare fraud criminal
provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;) (42 U.S.C. Section
1320d et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), and the civil monetary penalties law (42 U.S.C. &sect; 1320a-7a); (iii)
HIPAA, as amended by the Health Information Technology for Economic Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the regulations
promulgated pursuant to such laws; and (v) any other similar local, state, federal, or foreign laws (collectively, the &ldquo;<B>Health
Care Laws</B>&rdquo;). Neither the Company, nor to the Company&rsquo;s knowledge, any of its officers, directors, employees or agents
have engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion
from Medicare, Medicaid, or any other state or federal healthcare program. The Company has not received written notice or other correspondence
of any claim, action, suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (&ldquo;<B>Action</B>&rdquo;)
from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is
in violation of any Health Care Laws, and, to the Company&rsquo;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action is threatened. The Company is not a party to and does not have any ongoing reporting obligations
pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order,
plan of correction or similar agreement imposed by any governmental or regulatory authority. Additionally, neither the Company, nor to
the Company&rsquo;s knowledge, any of its employees, officers or directors, has been excluded, suspended or debarred from participation
in any U.S. state or federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or
exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Consents and Permits</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries have
made all filings, applications and submissions required by, possess and are operating in compliance with all approvals, licenses, certificates,
certifications, clearances, consents, grants, exemptions, marks, notifications, orders, permits and other authorizations issued by, the
appropriate federal, state or foreign Governmental Authority (including the United States Food and Drug Administration (the &ldquo;<B><U>FDA</U></B>&rdquo;),
the United States Drug Enforcement Administration or any other foreign, federal, state, provincial or local Government Authorities engaged
in the regulation of clinical trials, pharmaceuticals, biologics or biohazardous substances or materials) necessary for the ownership
or lease of their respective properties or to conduct its businesses as described in the Registration Statement or the Prospectus (collectively,
&ldquo;<B><U>Permits</U></B>&rdquo;), except for such Permits the failure of which to possess, obtain or file would not reasonably be
expected to have a Material Adverse Effect; the Company and its Subsidiaries are in compliance with the terms and conditions of all such
Permits, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect; all of the
Permits are valid and in full force and effect, except where any invalidity, individually or in the aggregate, would not reasonably be
expected to have a Material Adverse Effect; and neither the Company nor any of its Subsidiaries has received any written notice relating
to the limitation, revocation, cancellation, suspension, modification or non-renewal of any such Permit which, if the subject of an unfavorable
decision, ruling or finding, would not reasonably be expected to have a Material Adverse Effect, or has any reason to believe that any
such license, certificate, permit or authorization will not be renewed in the ordinary course. To the extent required by applicable Laws
of the FDA, the Company or the applicable Subsidiary has submitted to the FDA an Investigational New Drug Application or amendment or
supplement thereto for each clinical trial it has conducted or sponsored or is conducting or sponsoring; all such submissions were in
material compliance with applicable Laws when submitted and no material deficiencies have been asserted by the FDA with respect to any
such submissions. The Company and each Subsidiary possess such valid and current certificates, authorizations or permits issued by the
appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct their respective businesses, and neither the
Company nor any Subsidiary has received, or has any reason to believe that it will receive, any notice of proceedings relating to the
revocation or modification of, or non-compliance with, any such certificate, authorization or permit which, if the subject of an unfavorable
decision, ruling or finding, would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Regulatory Filings</U>. Except as disclosed in the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries
has failed to file with the applicable Governmental Authority (including the FDA, or any foreign, federal, state, provincial or local
Governmental Authority performing functions similar to those performed by the FDA) any required filing, declaration, listing, registration,
report or submission, except for such failures that, individually or in the aggregate, would not reasonably be expected to have a Material
Adverse Effect; except as disclosed in the Registration Statement and the Prospectus, all such filings, declarations, listings, registrations,
reports or submissions were in compliance with applicable Laws when filed and no deficiencies have been asserted by any applicable regulatory
authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies
that, individually or in the aggregate, would not have a Material Adverse Effect. The Company has operated and currently is, in all material
respects, in compliance with the United States Federal Food, Drug, and Cosmetic Act, all applicable rules and regulations of the FDA
and other federal, state, local and foreign Governmental Authority exercising comparable authority. The Company has no knowledge of any
studies, tests or trials not described in the Registration Statement and the Prospectus the results of which reasonably call into question
in any material respect the results of the studies, tests and trials described in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Intellectual Property</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries
own, possess, license or have other rights to use all foreign and domestic patents, patent applications, trade and service marks, trade
and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, Internet domain names, know-how
and other intellectual property (collectively, the &ldquo;<B><U>Intellectual Property</U></B>&rdquo;) necessary for the conduct of their
respective businesses as now conducted except to the extent that the failure to own, possess, license or otherwise hold adequate rights
to use such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in
the Registration Statement and the Prospectus (i) there are no rights of third parties to any such Intellectual Property owned by the
Company and its Subsidiaries, except for licenses granted in the ordinary course to third parties; (ii) to the Company&rsquo;s knowledge,
there is no infringement by third parties of any such Intellectual Property; (iii) there is no pending or, to the Company&rsquo;s knowledge,
threatened action, suit, proceeding or claim by others challenging the Company&rsquo;s and its Subsidiaries&rsquo; rights in or to any
such Intellectual Property, and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding
or claim; (iv) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging
the validity or scope of any such Intellectual Property; (v) there is no pending or, to the Company&rsquo;s knowledge, threatened action,
suit, proceeding or claim by others that the Company and its Subsidiaries infringe or otherwise violate any patent, trademark, copyright,
trade secret and its proprietary rights of others; (vi) to the Company&rsquo;s knowledge, there is no third-party U.S. patent or published
U.S. patent application which contains claims for which an Interference Proceeding (as defined in 35 U.S.C. &sect; 135) has been commenced
against any patent or patent application described in the Registration Statement and the Prospectus as being owned by or licensed to
the Company; and (vii) the Company and its Subsidiaries have complied with the material terms of each agreement pursuant to which Intellectual
Property has been licensed to the Company or such Subsidiary, and all such agreements are in full force and effect, except, in the case
of any of clauses (i)-(vii) above, for any such infringement by third parties or any such pending or threatened suit, action, proceeding
or claim as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Clinical Studies</U>. The preclinical studies and tests and clinical trials described in the Registration Statement and the Prospectus
were, and, if still pending, are, to the Company&rsquo;s knowledge, being conducted in all material respects in accordance with the experimental
protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product
candidates comparable to those being developed by the Company; the descriptions of such studies, tests and trials, and the results thereof,
contained in the Registration Statement and the Prospectus are accurate and complete in all material respects; the Company is not aware
of any tests, studies or trials not described in the Registration Statement and the Prospectus, the results of which reasonably call
into question the results of the tests, studies and trials described in the Registration Statement and the Prospectus; and the Company
has not received any written notice or correspondence from the FDA or any foreign, state or local Governmental Authority exercising comparable
authority or any institutional review board or comparable authority requiring the termination, suspension, clinical hold or material
modification of any tests, studies or trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Market Capitalization</U>. At the time the Registration Statement was originally declared effective, and at the time the Company&rsquo;s
most recent Annual Report on Form 10-K was filed with the Commission, the Company met the then applicable requirements for the use of
Form S-3 under the Securities Act, including, but not limited to, General Instruction I.B.1 of Form S-3. The Company is not a shell company
(as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously and if
it has been a shell company at any time previously, has filed current Form 10 information (as defined in Instruction I.B.6 of Form S-3)
with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>FINRA Matters</U>. As of the date of the Prospectus, the information provided to the Agent by the Company, its counsel, and its officers
and directors for purposes of the Agent&rsquo;s compliance with applicable FINRA rules in connection with the offering of the Shares
is true, complete, and correct and compliant with FINRA&rsquo;s rules. As of the date of the Prospectus, the Company meets the definition
of the term &ldquo;experienced issuer&rdquo; specified in FINRA Rule 5110(j)(6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>No Material Defaults</U>. Neither the Company nor any of its Subsidiaries has defaulted on any installment on indebtedness for borrowed
money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected
to have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the
filing of its last Annual Report on Form 10-K, indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred
stock or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which
defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Certain Market Activities</U>. Neither the Company nor any of its Subsidiaries has taken, directly or indirectly, any action designed
to or that would reasonably be expected to cause or result in stabilization or manipulation of the price of the Placement Shares or of
any &ldquo;reference security&rdquo; (as defined in Rule 100 of Regulation M under the Exchange Act (&ldquo;<B><U>Regulation M</U></B>&rdquo;))
with respect to the Placement Shares, whether to facilitate the sale or resale of the Placement Shares or otherwise, and has taken no
action which would directly or indirectly violate Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Broker/Dealer Relationships</U>. Neither the Company nor any of its Subsidiaries (i) is required to register as a &ldquo;broker&rdquo;
or &ldquo;dealer&rdquo; in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries,
controls or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo; (within the meaning set
forth in the FINRA Manual).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>No Reliance</U>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice
in connection with the offering and sale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Taxes</U>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise disclosed
in or contemplated by the Registration Statement and the Prospectus, no tax deficiency has been determined adversely to the Company or
any of its Subsidiaries which has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been
or might be asserted or threatened against it which would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Title to Real and Personal Property</U>. Except as set forth in the Registration Statement or the Prospectus, the Company and its
Subsidiaries have good and marketable title in fee simple to all items of real property owned by them, and good and valid title to all
personal property described in the Registration Statement or the Prospectus as being owned by them that are material to the businesses
of the Company or such Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those matters that (i) do
not materially interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries or (ii)
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Any real or personal property
described in the Registration Statement or the Prospectus as being leased by the Company and any of its Subsidiaries is held by them
under valid, existing and enforceable leases, except those that (A) do not materially interfere with the use made or proposed to be made
of such property by the Company or any of its Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate,
to have a Material Adverse Effect. Each of the properties of the Company and its Subsidiaries complies with all applicable Laws (including
building and zoning Laws and Laws relating to access to such properties), except if and to the extent disclosed in the Registration Statement
or the Prospectus or except for such failures to comply that would not, individually or in the aggregate, reasonably be expected to interfere
in any material respect with the use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have
a Material Adverse Effect. None of the Company or its Subsidiaries has received from any Governmental Authorities any notice of any condemnation
of, or zoning change affecting, the properties of the Company and its Subsidiaries, and the Company knows of no such condemnation or
zoning change which is threatened, except for such that would not reasonably be expected to interfere in any material respect with the
use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect, individually
or in the aggregate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Environmental Laws</U>. Except as set forth in the Registration Statement or the Prospectus, the Company and its Subsidiaries (i)
are in compliance with any and all applicable federal, state, local and foreign Laws relating to the protection of human health and safety
(with respect to exposure to chemicals in the environment), the environment or hazardous or toxic substances or wastes, pollutants or
contaminants (collectively, &ldquo;<B><U>Environmental Laws</U></B>&rdquo;); (ii) have received and are in compliance with all permits,
licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses as described
in the Registration Statement or the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation
or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case
of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals
or liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Disclosure Controls</U>. The Company and each of its Subsidiaries maintain systems of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company&rsquo;s internal control over financial reporting is effective, and the Company is not aware of any material
weaknesses in its internal control over financial reporting (in each case, other than as set forth in the Registration Statement or Prospectus).
Since the date of the latest audited financial statements of the Company included in the Prospectus, there has been no change in the
Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company&rsquo;s internal control over financial reporting (other than as set forth in the Registration Statement or Prospectus).
The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and
designed such disclosure controls and procedures to ensure that material information relating to the Company and each of its Subsidiaries
is made known to the certifying officers by others within those entities, particularly during the period in which the Company&rsquo;s
Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, is being prepared. The Company&rsquo;s certifying officers
have evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures as of a date within 90 days prior to the filing
date of the Form 10-K for the fiscal year ended December 31, 2021 (such date, the <B>&ldquo;<U>Evaluation Date</U></B>&rdquo;). The Company
presented in its Form 10-K for the fiscal year ended December 31, 2021 the conclusions of the certifying officers about the effectiveness
of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have
been no significant changes in the Company&rsquo;s internal controls (as such term is defined in Item 307(b) of Regulation S-K under
the Securities Act) or, to the Company&rsquo;s knowledge, in other factors that could significantly affect the Company&rsquo;s internal
controls, other than as set forth in the Registration Statement and Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Sarbanes-Oxley</U>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers,
in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules
and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the Company (or
each former principal executive officer of the Company and each former principal financial officer of the Company as applicable) has
made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements
and other documents required to be filed by it or furnished by it to the Commission. For purposes of the preceding sentence, &ldquo;principal
executive officer&rdquo; and &ldquo;principal financial officer&rdquo; shall have the meanings given to such terms in the Sarbanes-Oxley
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>Brokers</U>. Neither the Company nor any of its Subsidiaries has incurred any liability for any finder&rsquo;s fees, brokerage commissions
or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to or pursuant
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Labor Disputes</U>. No labor disturbance by or dispute with employees of the Company or any of its Subsidiaries exists or, to the
knowledge of the Company, is threatened which would reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Investment Company Act</U>. Neither the Company nor any of its Subsidiaries is or, after giving effect to the offering and sale of
the Placement Shares, will be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company,&rdquo;
as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<B><U>Investment Company Act</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Operations</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material
respects with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
1970, as amended, the money laundering Laws of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental
Authority (collectively, the &ldquo;<B><U>Money Laundering Laws</U></B>&rdquo;); and no action, suit or proceeding by or before any Governmental
Authority involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Off-Balance Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the Company,
and/or any of its affiliates and any unconsolidated entity, including any structural finance, special purpose or limited purpose entity
(each, an &ldquo;<B><U>Off-Balance Sheet Transaction</U></B>&rdquo;) that could reasonably be expected to affect materially the Company&rsquo;s
liquidity or the availability of or requirements for its capital resources, including those Off-Balance Sheet Transactions described
in the Commission&rsquo;s Statement about Management&rsquo;s Discussion and Analysis of Financial Conditions and Results of Operations
(Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Prospectus which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Underwriter Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other &ldquo;at the market&rdquo;
or continuous equity transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>ERISA</U>. To the knowledge of the Company, each material employee benefit plan, within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (&ldquo;<B><U>ERISA</U></B>&rdquo;), that is maintained, administered or contributed
to by the Company or any of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained
in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including ERISA
and the Internal Revenue Code of 1986, as amended (the &ldquo;<B><U>Code</U></B>&rdquo;); no prohibited transaction, within the meaning
of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material liability to the Company with respect
to any such plan, excluding transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is
subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no &ldquo;accumulated funding deficiency&rdquo; as defined
in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding
for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using
reasonable actuarial assumptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Forward-Looking Statements</U>. Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined
by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i)
was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions,
estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those
factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made
with the knowledge of an executive officer or director of the Company that is was false or misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Agent Purchases</U>. The Company acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent
permitted under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own account while this Agreement is in
effect, <I>provided</I>, that (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent
the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &ldquo;riskless principal&rdquo;
or in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by
the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>Margin Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the
Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of
the Federal Reserve System or any other regulation of such Board of Governors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>Insurance</U>. The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks
as the Company and each of its Subsidiaries reasonably believe are adequate for the conduct of their business and as is customary for
companies engaged in similar businesses in similar industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>No Improper Practices</U>. (i) Neither the Company nor its Subsidiaries, nor any director, officer, or, to the Company&rsquo;s knowledge,
employee of the Company or any Subsidiary nor, to the Company&rsquo;s knowledge, any agent, affiliate or other person acting on behalf
of the Company or any Subsidiary has, in the past five years, made any unlawful contributions to any candidate for any political office
(or failed fully to disclose any contribution in violation of applicable Law) or made any contribution or other payment to any official
of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public duty
in violation of any applicable Law or of the character required to be disclosed in the Prospectus; (ii) no relationship, direct or indirect,
exists between or among the Company or any Subsidiary or, to the Company&rsquo;s knowledge, any affiliate of any of them, on the one
hand, and the directors, officers and stockholders of the Company or any Subsidiary, on the other hand, that is required by the Securities
Act to be described in the Registration Statement and the Prospectus that is not so described; (iii) no relationship, direct or indirect,
exists between or among the Company or any Subsidiary or, to the Company&rsquo;s knowledge, any affiliate of them, on the one hand, and
the directors, officers, or stockholders of the Company or any Subsidiary, on the other hand, that is required by the rules of FINRA
to be described in the Registration Statement or the Prospectus that is not so described; (iv) except as described in the Registration
Statement and the Prospectus, there are no material outstanding loans or advances or material guarantees of indebtedness by the Company
or any Subsidiary to or, to the Company&rsquo;s knowledge, for the benefit of any of their respective officers or directors or any of
the members of the families of any of them; and (v) the Company has not offered, or caused any placement agent to offer, Common Stock
to any person with the intent to influence unlawfully (A) a customer or supplier of the Company or any Subsidiary to alter the customer&rsquo;s
or supplier&rsquo;s level or type of business with the Company or any Subsidiary or (B) a trade journalist or publication to write or
publish favorable information about the Company or any Subsidiary or any of their respective products or services; and (vi) neither the
Company nor any Subsidiary nor any director, officer or employee of the Company or any Subsidiary nor, to the Company&rsquo;s knowledge,
any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has (A) violated or is in violation of any applicable
provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery or anti-corruption Law
(collectively, &ldquo;<B>Anti-Corruption Laws</B>&rdquo;), (B) promised, offered, provided, attempted to provide or authorized the provision
of anything of value, directly or indirectly, to any person for the purpose of obtaining or retaining business, influencing any act or
decision of the recipient or securing any improper advantage, or (C) made any payment of funds of the Company or any Subsidiary or received
or retained any funds in violation of any Anti-Corruption Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<U>Status Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule 405 under the Securities
Act at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)
<U>No Misstatement or Omission in an Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue date and
as of each Applicable Time (as defined in <U>Section 23</U> below), did not, does not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated
document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in
or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by
the Agent specifically for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)
<U>No Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares nor the consummation
of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof and
thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute
a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of
the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as may have been waived and (ii) such
conflicts, breaches and defaults that would not reasonably be expected to have a Material Adverse Effect; nor will such action result
in (x) any violation of the provisions of the organizational or governing documents of the Company, or (y) any material violation of
the provisions of any statute or any order, rule or regulation applicable to the Company or of any Governmental Authority having jurisdiction
over the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)
<U>Sanctions</U>. (i) The Company represents that neither the Company nor any of its Subsidiaries (collectively, the &ldquo;<B><U>Entity</U></B>&rdquo;)
or any director, officer, employee, agent, affiliate or representative of the Entity, is a government, individual, or entity (in this
paragraph (ww), &ldquo;<B><U>Person</U></B>&rdquo;) that is, or is owned or controlled by a Person that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
the subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;<B><U>OFAC</U></B>&rdquo;),
the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury or other relevant sanctions authorities, including,
without limitation, designation on OFAC&rsquo;s Specially Designated Nationals and Blocked Persons List or OFAC&rsquo;s Foreign Sanctions
Evaders List (as amended, collectively, &ldquo;<B><U>Sanctions</U></B>&rdquo;), nor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country
or territory (including, without limitation, Cuba, Iran, North Korea, Syria, the so-called Donetsk People&rsquo;s Republic, the so-called
Luhansk People&rsquo;s Republic and the Crimea Region of the Ukraine) (the &ldquo;<B>Sanctioned Countries</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Entity represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions or is a Sanctioned Country; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Entity represents and covenants that, except as detailed in the Registration Statement and the Prospectus, for the past five years,
it has not engaged in, it is not now engaging in, and will not engage in, any dealings or transactions with any Person, or in any country
or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or is or was a Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)
<U>Stock Transfer Taxes</U>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required
to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid
or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(yy)
<U>Compliance with Laws</U>. Each of the Company and its Subsidiaries: (i) is and at all times has been in compliance with all statutes,
rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company
or its Subsidiaries (&ldquo;<B><U>Applicable Laws</U></B>&rdquo;), except as would not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect; (ii) has not received any FDA Form 483, notice of adverse finding, warning letter,
untitled letter or other correspondence or notice from the FDA or any other Governmental Authority alleging or asserting noncompliance
in any material respect with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements
or amendments thereto required by any such Applicable Laws (&ldquo;<B><U>Authorizations</U></B>&rdquo;); (iii) possesses all material
Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such
Authorizations; (iv) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action from any Governmental Authority or third party alleging that any product operation or activity is in material violation
of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Authority or third party is considering any
such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received notice that any Governmental Authority
has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such
Governmental Authority is considering such action; (vi) has filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete
and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission); and (vii) has
not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall,
market withdrawal or replacement, safety alert, post-sale warning, &ldquo;dear healthcare provider&rdquo; letter, or other notice or
action relating to the alleged lack of safety or efficacy of any product or any alleged material product defect or violation and, to
the Company&rsquo;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(zz)
<U>Privacy and Data Protection</U>. The Company and its Subsidiaries have operated their business in a manner compliant in all material
respects with all United States federal, state, local and non-United States privacy, data security and data protection laws and regulations
applicable to the Company&rsquo;s collection, use, transfer, protection, disposal, disclosure, handling, storage and analysis of personal
data. The Company and its Subsidiaries have been and are in compliance in all material respects with internal policies and procedures
designed to ensure the integrity and security of the data collected, handled or stored in connection with its business; the Company and
its Subsidiaries have been and are in compliance in all material respects with internal policies and procedures designed to ensure compliance
with the Health Care Laws that govern privacy and data security and take, and have taken reasonably appropriate steps designed to assure
compliance with such policies and procedures. The Company and its Subsidiaries have taken reasonable steps to maintain the confidentiality
of its personally identifiable information, protected health information, consumer information and other confidential information of
the Company, its Subsidiaries and any third parties in its possession (&ldquo;<B><U>Sensitive Company Data</U></B>&rdquo;). The tangible
or digital information technology systems (including computers, screens, servers, workstations, routers, hubs, switches, networks, data
communications lines, technical data and hardware), software and telecommunications systems used or held for use by the Company and its
Subsidiaries (the &ldquo;<B><U>Company IT Assets</U></B>&rdquo;) are adequate and operational for, in accordance with their documentation
and functional specifications, the business of the Company and its Subsidiaries as now operated and as currently proposed to be conducted
as described in the Registration Statement and the Prospectus. The Company and its Subsidiaries have used reasonable efforts to establish,
and have established, commercially reasonable disaster recovery and security plans, procedures and facilities for the business consistent
with industry standards and practices in all material respects, including, without limitation, for the Company IT Assets and data held
or used by or for the Company and its Subsidiaries. The Company and its Subsidiaries have not suffered or incurred any security breaches,
compromises or incidents with respect to any Company IT Asset or Sensitive Company Data, except where such breaches, compromises or incidents
would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect; and there has been no unauthorized
or illegal use of or access to any Company IT Asset or Sensitive Company Data by any unauthorized third party. The Company and its Subsidiaries
have not been required to notify any individual of any information security breach, compromise or incident involving Sensitive Company
Data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aaa)
<U>Related-Party Transactions</U>. There are no business relationships or related-party transactions involving the Company or any of
its Subsidiaries or any other person required to be described in the Registration Statement or the Prospectus that have not been described
as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bbb)
<U>No Rights to Purchase Preferred Stock</U>. The issuance and sale of the Placement Shares as contemplated hereby will not cause any
holder of any shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants
or other rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of preferred
stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ccc)
<U>Statistical and Market-Related Data</U>. All statistical, demographic and market related data included in the Registration Statement
or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate or represent the Company&rsquo;s
good faith estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ddd)
<U>No Contract Terminations</U>. Except as disclosed in the Registration Statement or the Prospectus, neither the Company nor any of
its Subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements
referred to or described in the Registration Statement or the Prospectus, and no such termination or non-renewal has been threatened
by the Company or any of its subsidiaries or, to the Company&rsquo;s knowledge, any other party to any such contract or agreement, which
threat of termination or non-renewal has not been rescinded as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with
this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set
forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Covenants of the Company</U>. The Company covenants and agrees with the Agent that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement Amendments</U>. After the date of this Agreement and during any period in which a Prospectus relating to any
Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement
may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), (i) the Company will notify the Agent promptly of the
time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference, has been filed with
the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed and of any request by the Commission
for any amendment or supplement to the Registration Statement or Prospectus or for additional information, (ii) the Company will prepare
and file with the Commission, promptly upon the Agent&rsquo;s reasonable request, any amendments or supplements to the Registration Statement
or Prospectus that, in the Agent&rsquo;s reasonable opinion, may be necessary or advisable in connection with the distribution of the
Placement Shares by the Agent (<I>provided</I>, <I>however</I>, that the failure of the Agent to make such request shall not relieve
the Company of any obligation or liability hereunder, or affect the Agent&rsquo;s right to rely on the representations and warranties
made by the Company in this Agreement and <I>provided</I>, <I>further</I>, that the only remedy the Agent shall have with respect to
the failure to make such filing shall be to cease making sales under this Agreement until such amendment or supplement is filed); (iii)
the Company will not file any amendment or supplement to the Registration Statement or Prospectus (except for documents incorporated
by reference therein) relating to the Placement Shares or a security convertible into the Placement Shares unless a copy thereof has
been submitted to Agent within a reasonable period of time before the filing and the Agent has not reasonably objected in writing within
two (2) Trading Days thereto (<I>provided</I>, <I>however</I>, that the failure of the Agent to make such objection shall not relieve
the Company of any obligation or liability hereunder, or affect the Agent&rsquo;s right to rely on the representations and warranties
made by the Company in this Agreement; and <I>provided</I>, <I>further</I>, that the only remedy the Agent shall have with respect to
the failure by the Company to obtain such consent shall be to cease making sales under this Agreement) and the Company will furnish to
the Agent at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration
Statement or Prospectus, except for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement
to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act
or, in the case of any document to be incorporated therein by reference, to be filed with the Commission as required pursuant to the
Exchange Act, within the time period prescribed (the determination to file or not file any amendment or supplement with the Commission
under this <U>Section 7(a)</U>, based on the Company&rsquo;s reasonable opinion or reasonable objections, shall be made exclusively by
the Company); <I>provided, however</I>, that the Company may delay any such amendment or supplement if, in the reasonable judgement of
the Company, it is in the best interests of the Company to do so. Until such time as the Company shall have corrected such misstatement
or omission or effected such compliance, the Company shall not notify the Agent to resume the offering of Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Notice of Commission Stop Orders</U>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof,
of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement,
of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop
order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agent promptly after it receives
any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or any
Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares or for additional information
related to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Delivery of Prospectus; Subsequent Changes</U>. During any period in which a Prospectus relating to the Placement Shares is required
to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares, (including in circumstances
where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), the Company will comply with
all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due
dates all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant
to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If the Company has omitted any information from
the Registration Statement pursuant to Rule 430B under the Securities Act, it will use its commercially reasonable efforts to comply
with the provisions of and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the Agent promptly
of all such filings if not available on EDGAR. If during such period any event occurs as a result of which the Prospectus as then amended
or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement
the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to suspend the
offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus
(at the expense of the Company) so as to correct such statement or omission or effect such compliance; <I>provided, however</I>, that
the Company may delay any such amendment or supplement if, in the reasonable judgement of the Company, it is in the best interests of
the Company to do so. Until such time as the Company shall have corrected such misstatement or omission or effected such compliance,
the Company shall not notify the Agent to resume the offering of Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Listing of Placement Shares</U>. Prior to the date of the first Placement Notice, the Company will use its commercially reasonable
efforts to cause the Placement Shares to be listed on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Delivery of Registration Statement and Prospectus</U>. The Company will furnish to the Agent and its counsel (at the expense of the
Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments
and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period in which a Prospectus
relating to the Placement Shares is required to be delivered under the Securities Act (including all documents filed with the Commission
during such period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such
quantities as the Agent may from time to time reasonably request and, at the Agent&rsquo;s request, will also furnish copies of the Prospectus
to each exchange or market on which sales of the Placement Shares may be made; <I>provided</I>, <I>however</I>, that the Company shall
not be required to furnish any document (other than the Prospectus) to the Agent to the extent such document is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Earning Statement</U>. The Company will make generally available to its security holders as soon as practicable, but in any event
not later than 15 months after the end of the Company&rsquo;s current fiscal quarter, an earning statement covering a 12-month period
that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act; <I>provided</I>, that the Company will be deemed to
have furnished such statement to its security holders to the extent it is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Use of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &ldquo;Use of Proceeds.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Notice of Other Sales</U>. Without the prior written consent of the Agent, the Company will not, directly or indirectly, offer to
sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire,
Common Stock during the period beginning on the fifth (5<SUP>th</SUP>) Trading Day immediately prior to the date on which any Placement
Notice is delivered to Agent hereunder and ending on the fifth (5<SUP>th</SUP>) Trading Day immediately following the final Settlement
Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended
prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly
or indirectly in any other &ldquo;at the market&rdquo; or continuous equity transaction offer to sell, sell, contract to sell, grant
any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities
convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common Stock prior to the sixtieth
(60<SUP>th</SUP>) day immediately following the termination of this Agreement; <I>provided</I>, <I>however</I>, that such restrictions
will not be required in connection with the Company&rsquo;s issuance or sale of (i) Common Stock, options to purchase shares of Common
Stock, restricted stock units or other similar equity securities (or Common Stock issuable upon the exercise of options or the vesting
of restricted stock units or other similar equity securities), pursuant to any employee or director stock option or benefits plan, stock
ownership plan or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment
plan) of the Company whether now in effect or hereafter implemented, (ii) Common Stock issuable upon conversion of securities or the
exercise of warrants, options or other rights or awards in effect or outstanding, and disclosed in filings by the Company available on
EDGAR or otherwise in writing to the Agent and (iii) Common Stock or securities convertible into or exchangeable for shares of Common
Stock as consideration for mergers, acquisitions, other business combinations or strategic alliances occurring after the date of this
Agreement which are not issued for capital raising purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Change of Circumstances</U>. The Company will, at any time during the pendency of a Placement Notice, advise the Agent promptly after
it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect
any opinion, certificate, letter or other document required to be provided to the Agent pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Due Diligence Cooperation</U>. The Company will cooperate with any reasonable due diligence review conducted by the Agent or its representatives
in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents
and senior corporate officers, during regular business hours and at the Company&rsquo;s principal offices, as the Agent may reasonably
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Required Filings Relating to Placement of Placement Shares</U>. The Company shall disclose, in its quarterly reports on Form 10-Q
and in its annual report on Form 10-K to be filed by the Company with the Commission from time to time, the number of the Placement Shares
sold through the Agent under this Agreement, and the net proceeds to the Company from the sale of the Placement Shares pursuant to this
Agreement during the relevant quarter or, in the case of an Annual Report on Form 10-K, during the fiscal year covered by such Annual
Report and the fourth quarter of such fiscal year. To the extent that the filing of a prospectus supplement with the Commission with
respect to the placement of Placement Shares is required under Rule 424(b) under the Securities Act, the Company agrees that on such
dates as the Securities Act shall require, the Company will (i) file a prospectus supplement with the Commission under the applicable
paragraph of Rule 424(b) under the Securities Act (each and every filing date under Rule 424(b), a &ldquo;<B><U>Filing Date</U></B>&rdquo;),
which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold through the Agent, the Net
Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares (provided that
to the extent permitted by the Securities Act and the rules and regulations thereunder, the Company may satisfy its obligations under
this Section 7(k)(i) by making a filing with the Commission in accordance with the Exchange Act that includes such information), and
(ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as
may be required by the rules or regulations of such exchange or market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Representation Dates; Certificate</U>. (1) On or prior to the date of the first Placement Notice and (2) each time the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to
an offering of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares
by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration
Statement or the Prospectus relating to the Placement Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material
amendment to the previously filed Form 10-K);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
files its quarterly reports on Form 10-Q under the Exchange Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
files a current report on Form 8-K containing amended financial information (other than information &ldquo;furnished&rdquo; pursuant
to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain
properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange Act
(each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &ldquo;<B><U>Representation Date</U></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information contained
in such Form 8-K is material) with a certificate dated the Representation Date, in the form and substance reasonably satisfactory to
the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary,
to relate to the Registration Statement and the Prospectus as amended or supplemented. The requirement to provide a certificate under
this <U>Section 7(l)</U> shall be automatically waived for any Representation Date occurring at a time during which no Placement Notice
is pending or a Suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions
for the sale of Placement Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring
Representation Date for which the requirement to provide a certificate under this <U>Section 7(l)</U> is not waived pursuant to the terms
hereof. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when
the Company relied on such waiver and did not provide the Agent with a certificate under this <U>Section 7(l)</U>, then before the Company
delivers the instructions for the sale of Placement Shares or the Agent sells any Placement Shares pursuant to such instructions, the
Company shall provide the Agent with a certificate in conformity with this <U>Section 7(l)</U> dated as of the date that the instructions
for the sale of Placement Shares are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Legal Opinion</U>. (1) On or prior to the date of the first Placement Notice and (2) within five (5) Trading Days of each Representation
Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section 7(l)</U> for which no waiver is applicable
and excluding the date of this Agreement, the Company shall cause to be furnished to the Agent a written opinion and negative assurance
letter of Haynes and Boone, LLP (&ldquo;<B><U>Company Counsel</U></B>&rdquo;), or other counsel reasonably satisfactory to the Agent,
in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to
the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented;
<I>provided, however</I>, that the Company shall not be required to furnish to the Agent more than one (1) opinion, other than in the
case of an opinion delivered on or prior to the date of the first Placement Notice, pursuant to this <U>Section 7(m)</U> per calendar
quarter; <I>provided, further</I>, that in lieu of such opinions for subsequent periodic filings under the Exchange Act, counsel may
furnish the Agent with a letter (a &ldquo;<B><U>Reliance Letter</U></B>&rdquo;) to the effect that the Agent may rely on a prior opinion
delivered under this <U>Section 7(m)</U> to the same extent as if it were dated the date of such letter (except that statements in such
prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of the date of
the Reliance Letter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Comfort Letter</U>. (1) On or prior to the date of the first Placement Notice and (2) within five (5) Trading Days of each Representation
Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section 7(l)</U> for which no waiver is applicable
and excluding the date of this Agreement, the Company shall cause its independent registered public accounting firm to furnish the Agent
letters (the &ldquo;<B><U>Comfort Letter</U></B>&rdquo;), dated the date the Comfort Letter is delivered, which shall meet the requirements
set forth in this <U>Section 7(n)</U>; <I>provided</I>, that if requested by the Agent, the Company shall cause a Comfort Letter to be
furnished to the Agent within ten (10) Trading Days of the date of occurrence of any material transaction or event requiring the filing
of a Current Report on Form 8-K containing material financial information (including the restatement of the Company&rsquo;s financial
statements). Additionally, on or prior to the date of the first Placement Notice, the Company shall cause its prior independent registered
public accounting firm, MaloneBailey LLP, to furnish the Agent a letter (the &ldquo;<B><U>MaloneBailey Comfort Letter</U></B>&rdquo;
and, collectively with the Comfort Letter, the &ldquo;<B><U>Comfort Letters</U></B>&rdquo;), dated the date the MaloneBailey Comfort
Letter is delivered, which shall meet the requirements set forth in this <U>Section 7(n)</U>. The Comfort Letters from the Company&rsquo;s
independent registered public accounting firm shall be in a form and substance satisfactory to the Agent, (i) confirming that they are
an independent registered public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight
Board, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters
ordinarily covered by accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters in connection with registered public offerings
(the first such letter, the &ldquo;<B><U>Initial Comfort Letter</U></B>&rdquo;), and (iii) updating the Initial Comfort Letter with any
information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate
to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter, with the exception of the MaloneBailey
Comfort Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Chief Financial Officer&rsquo;s Certificate</U>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading
Days of each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section 7(l)
</U>for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause to be furnished to the Agent
a certificate executed by the Chief Financial Officer of the Company, dated as of such date, in the form and substance reasonably satisfactory
to the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Market Activities; Compliance with Regulation M</U>. The Company will not, directly or indirectly, (i) take any action designed to
cause or result in, or that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in violation
of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Investment Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any
of its Subsidiaries will be or become, at any time prior to the termination of this Agreement, required to register as an &ldquo;investment
company,&rdquo; as such term is defined in the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>No Offer to Sell</U>. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agent in its capacity
as agent hereunder, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity
as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities
Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Blue Sky and Other Qualifications</U><I>. </I>The Company will use its commercially reasonable efforts, in cooperation with the Agent,
to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under
the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may designate and to maintain
such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for
less than one year from the date of this Agreement); <I>provided</I>, <I>however</I>, that the Company shall not be obligated to file
any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in
which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company will file such statements
and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect
for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Sarbanes-Oxley Act</U>. The Company and the Subsidiaries will maintain and keep accurate books and records reflecting their assets
and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with GAAP and including those policies and
procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and
dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the
preparation of the Company&rsquo;s consolidated financial statements in accordance with GAAP, (iii) that receipts and expenditures of
the Company are being made only in accordance with management&rsquo;s and the Company&rsquo;s directors&rsquo; authorization, and (iv)
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&rsquo;s
assets that could have a material effect on its financial statements. The Company and the Subsidiaries will maintain such controls and
other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable
regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files
or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed
by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&rsquo;s
management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure and to ensure that material information relating to the Company or the Subsidiaries
is made known to them by others within those entities, particularly during the period in which such periodic reports are being prepared.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Secretary&rsquo;s Certificate; Further Documentation</U>. Prior to the date of the first Placement Notice, the Company shall deliver
to the Agent a certificate of the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date,
certifying as to (i) the Certificate of Formation of the Company, (ii) the Bylaws of the Company, (iii) the resolutions of the Board
of Directors of the Company (or an authorized committee thereof) authorizing the execution, delivery and performance of this Agreement
and the issuance of the Placement Shares and (iv) the incumbency of the officers duly authorized to execute this Agreement and the other
documents contemplated by this Agreement. Within five (5) Trading Days of each Representation Date, the Company shall have furnished
to the Agent such further information, certificates and documents as the Agent may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Payment of Expenses</U>. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including
(i) the preparation and filing of the Registration Statement, including any fees required by the Commission, and the printing or electronic
delivery of the Prospectus as originally filed and of each amendment and supplement thereto, in such number as the Agent shall deem necessary,
(ii) the printing and delivery to the Agent of this Agreement and such other documents as may be required in connection with the offering,
purchase, sale, issuance or delivery of the Placement Shares, (iii) the preparation, issuance and delivery of the certificates, if any,
for the Placement Shares to the Agent, including any stock or other transfer taxes and any capital duties, stamp duties or other duties
or taxes payable upon the sale, issuance or delivery of the Placement Shares to the Agent, (iv) the fees and disbursements of the counsel,
accountants and other advisors to the Company, (v) the reasonable and documented fees and expenses of Agent including but not limited
to the fees and expenses of the counsel to the Agent, payable upon the execution of this Agreement, (a) in an amount not to exceed $75,000
in connection with the execution of this Agreement and (b) in an amount not to exceed $25,000 per calendar quarter thereafter payable
in connection with each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section
7(l)</U> for which no waiver is applicable and excluding the date of this Agreement, (vi) the qualification or exemption of the Placement
Shares under state securities laws in accordance with the provisions of <U>Section 7(r)</U> hereof, including filing fees, but excluding
fees of the Agent&rsquo;s counsel, (vii) the printing and delivery to the Agent of copies of any Permitted Issuer Free Writing Prospectus
and the Prospectus and any amendments or supplements thereto in such number as the Agent shall deem reasonably necessary, (viii) the
preparation, printing and delivery to the Agent of copies of the blue sky survey, (ix) the fees and expenses of the transfer agent and
registrar for the Common Stock, (x) the filing and other fees incident to any review by FINRA of the terms of the sale of the Placement
Shares including the fees of the Agent&rsquo;s counsel (subject to the cap, set forth in clause (v) above), and (xi) the fees and expenses
incurred in connection with the listing of the Placement Shares on the Exchange. The Company agrees to pay the fees and expenses of counsel
to the Agent set forth in clause (v) above by wire transfer of immediately available funds directly to such counsel upon presentation
of an invoice containing the requisite payment information prepared by such counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Conditions to Agent&rsquo;s Obligations</U>. The obligations of the Agent hereunder with respect to a Placement will be subject to
the continuing accuracy and completeness of the representations and warranties made by the Company herein (other than those representations
and warranties expressly made as of a specified time), to the due performance by the Company of its obligations hereunder, to the completion
by the Agent of a due diligence review satisfactory to it in its reasonable judgment, and to the continuing satisfaction (or waiver by
the Agent in its sole discretion) of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement Effective</U>. The Registration Statement shall have become effective and shall be available for the (i) resale
of all Placement Shares issued to the Agent and not yet sold by the Agent and (ii) sale of all Placement Shares contemplated to be issued
by any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>No Material Notices</U>. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request
for additional information from the Commission or any other federal or state Governmental Authority during the period of effectiveness
of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement
or the Prospectus, which amendments and supplements have not, as of the time of such Placement, been made; (ii) the issuance by the Commission
or any other federal or state Governmental Authority of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension of
the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening
of any proceeding for such purpose; or (iv) the occurrence of any event that makes any statement of a material fact made in the Registration
Statement or the Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect
or that requires the making of any changes in the Registration Statement, the Prospectus or documents so that, in the case of the Registration
Statement, it will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will not contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>No Misstatement or Material Omission</U>. The Agent shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&rsquo;s reasonable opinion is material,
or omits to state a fact that in the Agent&rsquo;s reasonable opinion is material and is required to be stated therein or is necessary
to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Material Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&rsquo;s reports filed with the Commission,
there shall not have been any material adverse change in the authorized capital stock of the Company or any Material Adverse Effect or
any development that would reasonably be expected to cause a Material Adverse Effect, or a downgrading in or withdrawal of the rating
assigned to any of the Company&rsquo;s securities (other than asset backed securities) by any rating organization or a public announcement
by any rating organization that it has under surveillance or review its rating of any of the Company&rsquo;s securities (other than asset
backed securities), the effect of which, in the case of any such action by a rating organization described above, in the reasonable judgment
of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable
or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Legal Opinions</U>. The Agent shall have received the opinions and negative assurance letters required to be delivered pursuant to
<U>Section 7(m)</U> on or before the date on which such delivery of such opinions is required pursuant to <U>Section 7(m)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Comfort Letter</U>. The Agent shall have received the Comfort Letter required to be delivered pursuant to <U>Section 7(n)</U> on or
before the date on which such delivery of such Comfort Letter is required pursuant to <U>Section 7(n)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Representation Certificate</U>. The Agent shall have received the certificate required to be delivered pursuant to <U>Section 7(l)
</U>on or before the date on which delivery of such certificate is required pursuant to <U>Section 7(l)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>No Suspension</U>. Trading in the Common Stock shall not have been suspended on the Exchange and the Common Stock shall not have been
delisted from the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Other Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to <U>Section 7(l)</U>, the Company
shall have furnished to the Agent such appropriate further information, opinions, certificates, letters and other documents as the Agent
may reasonably request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Securities Act Filings Made</U>. All filings with the Commission required by Rule 424 under the Securities Act to have been filed
prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing
by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Approval for Listing</U>. The Placement Shares shall either have been (i) approved for listing on the Exchange, subject only to notice
of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to,
the issuance of any Placement Notice and the Exchange shall have reviewed such application and not provided any objections thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>FINRA</U>. If applicable, FINRA shall have raised no objection to the terms of this offering and the amount of compensation allowable
or payable to the Agent as described in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>No Termination Event</U>. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant
to <U>Section 12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Indemnification and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Company Indemnification</U>. The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners,
members, directors, officers, employees and agents and each person, if any, who controls the Agent or any affiliate within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto),
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein
not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer
Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, made in
the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus (or any amendment or supplement thereto); <I>provided
</I>that (subject to <U>Section 10(d)</U> below) any such settlement is effected with the written consent of the Company, which consent
shall not unreasonably be delayed or withheld; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
against any and all expense whatsoever, as incurred (including the reasonable and documented fees and disbursements of counsel), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Authority,
commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement
or omission, made in the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus (or any amendment or supplement
thereto) (whether or not a party), to the extent that any such expense is not paid under (i) or (ii) above,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>provided</I>,
<I>however</I>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the
Agent Information (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Agent Indemnification</U>. The Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company
who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the indemnity contained
in <U>Section 10(a)</U>, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions,
made in the Registration Statement (or any amendments thereto), the Prospectus (or any amendment or supplement thereto) or any Issuer
Free Writing Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating to the
Agent and furnished to the Company in writing by the Agent expressly for use therein. The Company hereby acknowledges that the only information
that the Agent has furnished to the Company expressly for use in the Registration Statement, the Prospectus, any Prospectus Supplement
or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) are the statements set forth in the seventh and eighth
paragraphs under the caption &ldquo;Plan of Distribution&rdquo; in the Prospectus (the &ldquo;<B><U>Agent Information</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Procedure</U>. Any party that proposes to assert the right to be indemnified under this <U>Section 10</U> will, promptly after receipt
of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or
parties under this <U>Section 10</U>, notify each such indemnifying party of the commencement of such action, enclosing a copy of all
papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that
it might have to any indemnified party otherwise than under this <U>Section 10</U> and (ii) any liability that it may have to any indemnified
party under the foregoing provision of this <U>Section 10</U> unless, and only to the extent that, such omission results in the forfeiture
of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies
the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects
by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified
party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory
to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense,
the indemnifying party will not be liable to the indemnified party for any other legal expenses except as provided below and except for
the reasonable and documented costs of investigation subsequently incurred by the indemnified party in connection with the defense. The
indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such
counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized
in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may
be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying
party, (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party
and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf
of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action or counsel
reasonably satisfactory to the indemnified party, in each case, within a reasonable time after receiving notice of the commencement of
the action; in each of which cases the reasonable and documented fees, disbursements and other charges of counsel will be at the expense
of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding
or related proceedings in the same jurisdiction, be liable for the reasonable and documented fees, disbursements and other charges of
more than one separate firm (plus local counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party
or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred.
An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent.
No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry
of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this <U>Section 10</U>
(whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an express and
unconditional release of each indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability
arising out of such litigation, investigation, proceeding or claim and (2) does not include a statement as to or an admission of fault,
culpability or a failure to act by or on behalf of any indemnified party. Without limiting the rights of indemnified parties set forth
under this Section 10, indemnified parties will reasonably cooperate with the indemnifying party or indemnifying parties in the investigation
and defense of any claim for which indemnification is sought hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Settlement Without Consent if Failure to Reimburse</U><I>. </I>If an indemnified party shall have requested an indemnifying party
to reimburse the indemnified party for reasonable and documented fees and expenses of counsel for which it is entitled to be reimbursed
under this <U>Section 10</U>, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by
<U>Section 10(a)(ii)</U> effected without its written consent if (1) such settlement is entered into more than 45 days after receipt
by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received notice of the terms of such settlement
at least 30 days prior to such settlement being entered into and (3) such indemnifying party shall not have reimbursed such indemnified
party in accordance with such request prior to the date of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Contribution</U>. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for
in the foregoing paragraphs of this <U>Section 10</U> is applicable in accordance with its terms but for any reason is held to be unavailable
or insufficient from the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses
and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement
of, any action, suit or proceeding or any claim asserted) to which the Company and the Agent may be subject in such proportion as shall
be appropriate to reflect the relative benefits received by the Company on the one hand and the Agent on the other hand. The relative
benefits received by the Company on the one hand and the Agent on the other hand shall be deemed to be in the same proportion as the
total net proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation
received by the Agent from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing
sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect
not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and
the Agent, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage,
or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and
their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the
Agent agree that it would not be just and equitable if contributions pursuant to this <U>Section 10(e)</U> were to be determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein.
The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect
thereof, referred to above in this <U>Section 10(e)</U> shall be deemed to include, for the purpose of this <U>Section 10(e)</U>, any
legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or
claim to the extent consistent with <U>Section 10(c)</U> hereof. Notwithstanding the foregoing provisions of this <U>Section 10(e)</U>,
the Agent shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person
found guilty of fraudulent misrepresentation (within the meaning of <U>Section 11(f)</U> of the Securities Act) will be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section 10(e)</U>, any person who controls
a party to this Agreement within the meaning of the Securities Act, any affiliates of the Agent and any officers, directors, partners,
employees or agents of the Agent or any of its affiliates, will have the same rights to contribution as that party, and each director
of the Company and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the
Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement
of any action against such party in respect of which a claim for contribution may be made under this <U>Section 10(e)</U>, will notify
any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties
from whom contribution may be sought from any other obligation it or they may have under this <U>Section 10(e)</U> except to the extent
that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution
is sought. Except for a settlement entered into pursuant to the last sentence of <U>Section 10(c)</U> hereof, no party will be liable
for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to <U>Section
10(c)</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Representations and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in <U>Section 10</U> of
this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive,
as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons, or the
Company (or any of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement
Shares and payment therefor or (iii) any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Agent may terminate this Agreement, by notice to the Company, as hereinafter specified at any time (1) if there has been, since the
time of execution of this Agreement or since the date as of which information is given in the Prospectus, any change, or any development
or event involving a prospective change, in the condition, financial or otherwise, or in the business, properties, earnings, results
of operations or prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course
of business, which individually or in the aggregate, in the sole judgment of the Agent is material and adverse and makes it impractical
or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (2) if there has occurred
any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities
or escalation thereof or other calamity or crisis or any change or development involving a prospective change in national or international
political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Agent, impracticable
or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in the Common
Stock has been suspended or limited by the Commission or the Exchange, or if trading generally on the Exchange has been suspended or
limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company
on any exchange or in the over-the-counter market shall have occurred and be continuing, (5) if a major disruption of securities settlements
or clearance services in the United States shall have occurred and be continuing, or (6) if a banking moratorium has been declared by
either U.S. Federal or New York authorities. Any such termination shall be without liability of any party to any other party except that
the provisions of <U>Section 8</U> (Payment of Expenses), <U>Section 10</U> (Indemnification and Contribution), <U>Section 11</U> (Representations
and Agreements to Survive Delivery), <U>Section 17</U> (Governing Law and Time; Waiver of Jury Trial) and <U>Section 18</U> (Consent
to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this
Agreement as provided in this <U>Section 12(a)</U>, the Agent shall provide the required notice as specified in <U>Section 13</U> (Notices).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall have the right, by giving ten (10) days&rsquo; notice as hereinafter specified to terminate this Agreement in its sole
discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party
except that the provisions of <U>Section 8</U>, <U>Section 10</U>, <U>Section 11</U>, <U>Section 17</U> and <U>Section 18</U> hereof
shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Agent shall have the right, by giving ten (10) days&rsquo; notice as hereinafter specified to terminate this Agreement in its sole
discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party
except that the provisions of <U>Section 8</U>, <U>Section 10</U>, <U>Section 11</U>, <U>Section 17</U> and <U>Section 18</U> hereof
shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
This Agreement shall remain in full force and effect unless terminated pursuant to <U>Sections 12(a)</U>, <U>(b)</U>, or <U>(c)</U> above
or otherwise by mutual agreement of the parties; <I>provided</I>, <I>however</I>, that any such termination by mutual agreement shall
in all cases be deemed to provide that <U>Section 8</U>, <U>Section 10</U>, <U>Section 11</U>, <U>Section 17</U> and <U>Section 18</U>
shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Any termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided</I>, <I>however</I>,
that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company,
as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares
shall settle in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Notices</U>. All notices or other communications required or permitted to be given by any party to any other party pursuant to the
terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agent, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">499
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Capital Markets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
(212) 307-3730</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">499
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
General Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
(212) 829-4708</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Financial Center</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston,
MA 02111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
John Rudy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
(617) 542-2241</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
if to the Company, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
MedTech Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1200
Summit Ave, Suite 414</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort
Worth, TX 76102</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Michael D. McNeil</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
and Boone, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2323
Victory Avenue, Suite 700</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
TX 75219</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Matthew L. Fry</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
(214) 200-0916</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile
transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business
Day, on the next succeeding Business Day, (ii) by Electronic Notice, as set forth below, (iii) on the next Business Day after timely
delivery to a nationally-recognized overnight courier and (iv) on the Business Day actually received if deposited in the U.S. mail (certified
or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &ldquo;<B><U>Business Day</U></B>&rdquo;
shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
electronic communication (&ldquo;<B><U>Electronic Notice</U></B>&rdquo;) shall be deemed written notice for purposes of this Section
13 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received
at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic
Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<B><U>Nonelectronic Notic</U>e</B>&rdquo;)
which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective
successors and the parties referred to in Section 10 hereof. References to any of the parties contained in this Agreement shall be deemed
to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations
under this Agreement without the prior written consent of the other party; <I>provided</I>, <I>however</I>, that the Agent may assign
its rights and obligations hereunder to an affiliate thereof without obtaining the Company&rsquo;s consent, so long as such affiliate
is a registered broker-dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Adjustments for Stock Splits</U>. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall
be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Entire Agreement; Amendment; Severability; Waiver</U>. This Agreement (including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof
may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or more of the
provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by
a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is
valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or
unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver
by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power,
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any right, power, or privilege hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
<U>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF
THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH
PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
<U>CONSENT TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED
HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE
OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS
BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED)
TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND
SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS
IN ANY MANNER PERMITTED BY LAW.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made
by facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions
Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Construction</U>. The section and exhibit headings herein are for convenience only and shall not affect the construction hereof. References
herein to any law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority shall be deemed to refer
to such law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority as amended, reenacted, supplemented
or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<U>Permitted Free Writing Prospectuses</U>. The Company represents, warrants and agrees that, unless it obtains the prior written consent
of the Agent (which consent shall not be unreasonably withheld, conditioned or delayed), and the Agent represents, warrants and agrees
that, unless it obtains the prior written consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed),
it has not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus,
or that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule 405, required to be filed with the Commission.
Any such free writing prospectus consented to by the Agent or by the Company, as the case may be, is hereinafter referred to as a &ldquo;Permitted
Free Writing Prospectus.&rdquo; The Company represents and warrants that it has treated and agrees that it will treat each Permitted
Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, and has complied and will comply
with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where
required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free writing prospectuses, if
any, listed in <U>Exhibit A</U> hereto are Permitted Free Writing Prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
<U>Absence of Fiduciary Relationship</U>. The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand,
and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether or not the Agent has advised or is advising the Company on other matters, and the Agent has no obligation to the Company with
respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
neither the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated
by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ from
those of the Company and the Agent and its affiliates have no obligation to disclose such interests and transactions to the Company by
virtue of any fiduciary, advisory or agency relationship or otherwise; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
it waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of fiduciary
duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agent
and its affiliates shall not have any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such
a fiduciary duty claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or
creditors of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.
<U>Definitions</U>. As used in this Agreement, the following terms have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Applicable
Time</U></B>&rdquo; means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement
and (iii) each Settlement Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Governmental
Authority</U></B>&rdquo; means (i) any federal, provincial, state, local, municipal, national or international government or governmental
authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court,
tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political subdivision
of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Issuer
Free Writing Prospectus</U></B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, relating to the
Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a &ldquo;road show&rdquo; that is a &ldquo;written
communication&rdquo; within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt
from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not
reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company&rsquo;s records pursuant to Rule 433(g) under the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Law</U></B>&rdquo;
means any and all laws, including all federal, state, local, municipal, national or foreign statutes, codes, ordinances, guidelines,
decrees, rules, regulations and by-laws and all judicial, arbitral, administrative, ministerial, departmental or regulatory judgments,
orders, directives, decisions, rulings or awards or other requirements of any Governmental Authority, binding on or affecting the person
referred to in the context in which the term is used and rules, regulations and policies of any stock exchange on which securities of
the Company are listed for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Rule
164</U></B>,&rdquo; &ldquo;<B><U>Rule 172</U></B>,&rdquo; &ldquo;<B><U>Rule 405</U></B>,&rdquo; &ldquo;<B><U>Rule 415</U></B>,&rdquo;
&ldquo;<B><U>Rule 424</U></B>,&rdquo; &ldquo;<B><U>Rule 424(b)</U></B>,&rdquo; &ldquo;<B><U>Rule 430B</U></B>,&rdquo; and &ldquo;<B><U>Rule
433</U></B>&rdquo; refer to such rules under the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to financial statements and schedules and other information that is &ldquo;contained,&rdquo; &ldquo;included&rdquo;
or &ldquo;stated&rdquo; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to
mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration
Statement or the Prospectus, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing
Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission)
shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to &ldquo;supplements&rdquo;
to the Prospectus shall include, without limitation, any supplements, &ldquo;wrappers&rdquo; or similar materials prepared in connection
with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<B><I>Signature
Page Follows</I></B>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below
for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SANARA
    MEDTECH INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael D. McNeil</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    D. McNeil </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED
    as of the date first-above written:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CANTOR
    FITZGERALD &amp; CO.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sage Kelly</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sage
    Kelly</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
Head of Investment Banking</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to ATM Sales Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Placement Notice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
    MedTech Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
    Fitzgerald &amp; Co. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    [&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Notice</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    202[&#9679;]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and subject to the conditions contained in the Sales Agreement between Sanara MedTech Inc., a Texas corporation (the &ldquo;<B><U>Company</U></B>&rdquo;),
and Cantor Fitzgerald &amp; Co. (&ldquo;<B><U>Agent</U></B>&rdquo;), dated February 24, 2023, the Company hereby requests that the Agent
sell up to [&#9679;] of the Company&rsquo;s common stock, par value $0.001 per share, at a minimum market price of $[&#9679;] per share,
during the time period beginning [month, day, time] and ending [month, day, time].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to 3.0% of the
aggregate gross proceeds from each sale of Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Representation Date Certificate Pursuant to Section 7(l)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, the duly qualified and elected [&bull;], of Sanara MedTech Inc., a Texas corporation (the &ldquo;<U>Company</U>&rdquo;),
does hereby certify in such capacity and on behalf of the Company, pursuant to <U>Section 7(l)</U> of the Sales Agreement, dated February
24, 2023 (the &ldquo;<U>Sales Agreement</U>&rdquo;), between the Company and Cantor Fitzgerald &amp; Co., that to the best of the knowledge
of the undersigned:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The representations and warranties of the Company in <U>Section 6</U> of the Sales Agreement are true and correct on and as of the date
hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties
that speak solely as of a specific date and which were true and correct as of such date; <I>provided</I>, <I>however</I>, that such representations
and warranties also shall be qualified by the disclosure included or incorporated by reference in the Registration Statement and Prospectus;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales
Agreement at or prior to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms used herein without definition shall have the meanings given to such terms in the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SANARA
    MEDTECH INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permitted
Free Writing Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 81px; width: 897px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
24, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
MedTech Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1200
Summit Ave</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
414</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort
Worth, TX 76102</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel for Sanara MedTech Inc., a Texas corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the
preparation of the Company&rsquo;s prospectus supplement, dated February 24, 2023 (the &ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;),
to the Registration Statement on Form S-3 (Registration No. 333-251652), filed by the Company with the Securities and Exchange Commission
(the &ldquo;<B><I>Commission</I></B>&rdquo;) on December 23, 2020, as thereafter declared effective on January 4, 2021 (the &ldquo;<B><I>Registration
Statement</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have acted as counsel to the Company in connection with an offering of up to $75,000,000 of shares (the &ldquo;<B><I>Shares</I></B>&rdquo;)
of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), that may be issued and
sold under that certain Controlled Equity Offering Sales Agreement executed by the Company and Cantor Fitzgerald &amp; Co. on February
24, 2023 (the &ldquo;<B><I>Sales Agreement</I></B>&rdquo;). The Prospectus Supplement relates to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering the opinion set forth herein, we have examined the originals, or photostatic or certified copies, of (i) the certificate of
formation and bylaws of the Company, each as amended and/or restated as of the date hereof; (ii) certain resolutions of the Board of
Directors of the Company and the Pricing Committee of the Board of Directors of the Company related to the filing of the Prospectus Supplement,
the authorization and issuance of the Shares and related matters; (iii) the Registration Statement and all exhibits thereto; (iv) the
Prospectus Supplement and the prospectus included in the Registration Statement dated January 4, 2021 (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;
and together with the Prospectus Supplement, the &ldquo;<B><I>Prospectus</I></B>&rdquo;); (v) the Sales Agreement; (vi) a certificate
executed by an officer of the Company, dated as of the date hereof, and (vii) such other records, documents and instruments as we deemed
relevant and necessary for purposes of the opinion stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon such certificates of officers of the Company and of public officials and statements and information furnished by officers
of the Company with respect to the accuracy of material factual matters contained therein which were not independently established by
us. In such examination we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals,
the conformity to original documents of all documents submitted to us as photostatic or certified copies, and the authenticity of the
originals of such copies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion expressed herein is limited to the laws of the State of Texas. We have not considered, and express no opinion, as to the laws
of any other state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, and subject to the assumptions, qualifications, limitations and exceptions set forth herein, we are of the opinion
that upon payment and delivery in accordance with the Sales Agreement, the Shares will be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; width: 40%"><B>Haynes and Boone, LLP</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2323
    Victory Avenue | Suite 700 | Dallas, TX 75219</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T:
    214.651.5000 | haynesboone.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 81px; width: 897px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an exhibit to the Company&rsquo;s Current Report on Form 8-K to be filed with the Commission
and to the use of our name in the Prospectus under the caption &ldquo;Legal Matters.&rdquo; In giving this consent, we do not admit that
we are within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, and the rules
and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Very
                                                                     truly yours,</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Haynes and Boone, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
    and Boone, LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "'!=@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $)(&<9]
M?;]*;O/]T_Y_"FAB%/U !_GU_P \UFQ:DDLCHI3Y)".+A'?RHY)89F>.+S7A
MECGA9##,(QAXU:1;H3VL%*/>V]EHV[^27_!(YI<_LXPE4G;6W3STT]>AIK("
M,L-H]SW_ "'^<>HIC3$?<57YQ_K I_53T/'7Z9%?&/[4'_!0?]C;]C:TDD_:
M1^/_ ("^'>J"PTK5H/"$U]=>)?B)?:/K-_=Z78ZYIGPQ\&6?B/XC:IX?;4+&
M^M;C7-/\+7.E6LMI.MQ=QF-A7\[_ ,5?^#M+X+:7JNF0? G]COXH?$;2)K64
M:O>?%+XF>#?@_J\&K>8P@M= T3PCI/QUB\1:9)$$>76IM7T1(9&:);.=4$S]
M=#+,=C%^XHU(/TC;_P GM]ZZ^1]/DW!O%W$$N;)\AQ.+I63YYQE1AJKZ5*CI
MQ=^G+*7KW_KK-T@X(4-TV&6,.6_N@;MN?JPH:YV@_NW9L!@J8P0Q(4>:^R$,
M?[ID!Y&,[E)_S^[C_@ZN_P""@K7,[6?P<_8_@L3,'M;>Y\#?&>\O(8N\<]\G
MQZM([ECSF1;&V7D@1   ==\.O^#K?]L+2O%5K>?%?]G;]G+QIX'BMM1ANO#G
MPY'Q(^%GB>YFFV_V7+#XP\0>,?BWI-K'IVW%Q"? \[WRLXAGTYF#KZG^JV=_
M] ]/_P "_P#MC[-^"OB'9O\ L>CHF[+%TFW9-I+WDKO;5K6VJ5VO[VO-P,LN
MT]@&W'^0_J/?T42$C.S _P![^0Q_G(K^7;]G;_@Z>_8Z^(L^EZ1^T)\)_BE^
MSEK5[=ZNVIZ[9"+XT?##P]HUCHZ:MIFHZKXB\*:9H?Q'ENM;/F64&G:1\'M3
MCMK@1M+J+Q2.T/\ 1#\(_P!H3X+?M >$?^$Z^!WQ/^'WQ=\'Q:C_ &/?>(/A
MOXOT;QEI^E:S)8Z5JT6C:Q+H5Q>G2-7CTG6])U+4M*U1;/4M(L]1L;N^M(K*
M<72^/7P6+P:_?4:DW=:VBK+RY=-]-6? YQPQQ%D,[YQEN*P%/6W[F52,GM_$
M4:D7Y)23?1,]MHJH;K!;]TVU6VDN'B8!)_*GEQ-'&A@B0K,)4D?S4)**0%9K
M=<QXP4444 %%%% !1110 4444 )DXSC\.F?S_K2;F/\ "?Q./YBF%B5'KD\]
M.GT^OZ55:<(2' &-A(W995?;@L-N/^>GW"_" _Q_+$(U*JO"26KMI>_RMT%=
MJ?LXPE4FU]G^DOZ^1;\P@99=OL3_ /6 _P _7 9#_ H?_@6#^6#_ )_2E)<Q
MC>Q*NB#>\A<Q1I$IBWR-(\:P@(DCOCS.1&<9._RY@8P>K#ZC/X=1^J_TK2#<
MKN5.<+=)+3\TR9N$(\E2K.%3NX)/[G&WX>I8WCOC]3_04%QV&?TJNCH?NH?3
MKG\^%/?UJ(W2A/,"CRV9 CJRRB028".HB,S^66.TN5 '+GY!NI34HVY:<IWT
MTM^C8H5:<_X<JE3TIM_E'\RZ7P 0,Y]^A].E(TA"@A<\X(ST_3FJ<=Y#(TL2
ME6>,@LJ21RNNXEHPT<9,RM)#Y<P!C^Y*,%@":M?,OJ/Y?X56B>VE^NGW]K?\
M.4XU.7EE>G4MNTKKSLU:WRZDI)&.,^N.WZ4W<?[A_7_"D!(3ODD ?IT]OI5"
M2\BB=E9E^4*6 ;;(@(9F>2.01[8U7R\.C2%F=EVC9EI]^WN4Y5&]E%-OMLNG
MG;?0N"E.;IP@YR6KLF[+SM;?Y:Z>3TZ**I)>*S*A3$C"4; )G(:"X-M,3L@8
M+%OP89)"AF4EMB*CE019$A(R%R?3//OCCM_GBC?@98!?;.3_ "&/Q_#-0)-&
M#A6&?]UN/P _SBJ@O4D9U\M6*%26CGC=-I:,.0J;IPP#,\0,/ERH(V\R,2@*
MXMMOFIRIKI=Z_HOF34<:<N>I*I3I]G!V^_E;_$UJ***10W<.Y'X'--9R.BAO
MHX_PJLUPO!7RR6S@;@.@+'(VLX.P%\%>,$'%0M>PJ51C&LC@D(TR1,0F'E*Q
MR,DKF.$23;4C&4C.=H8&FE):NG*WS_+1F+G%S]BYU*=3SIN__DT+?H: <=QC
M]:-X[8_4?T-5#/U^52%!WG]X,-P%6/$0\W<QQE>G8$G;3W=!]Y#Z=<?EPQ[>
MM*"E+XH2AZV_S7<J=6E#^)*I#U@U^<66B2!G&?7V_2FAB>B_K_\ 6IH8A3]0
M ?Y]?\\U5>X:,X<$$[=OS/M)8RXRWED*/D3<0&V^9DC 4R4H2FO==M^EWIO9
M>7S*YI<_LXTY5)VZ?\#3^M"V)">J@#_?!/Y ?Y_*EW^F#_P+'\P*SOM$:",M
MP\N[RHWWQ/)Y9)E\N*6))Y'CC!DVB+YN,, =PE$_[O>\7E[@S)N9P&4,^P$%
M#(CM&%=D:(%&8QY9EYB;DU^Z@V_-?DF[O[A)TU4]DJLZE3LH)O\ \EA9?>6?
M-]E_[[_^QH\WV7_OO_[&J'VI?[S_ /?AO\:/M2_WG_[\-_C1ST^U3_P"?_R!
MC]8I_P#05@__ "J:6_Z?GC^8%&\^@_[[%0"=6X!##OA6/Z!?ZU&MPCQK)Y<J
MY&=KI)$P^L<R)*.>FY 2.<8(IQYG\5-P]7K]UT:3G&G_ !)U(>L/_M"WO&,X
M_P "?KC^E1F;'0*?K(%_/(Q3$??'E@0.3CCK[YYZ=OU]*C,')W0L!M0\2KN&
M6(<E6"@1Q\'<&;=E@$#*-Y:44URRJ36]K6OYV<5]Q4Y4X2]G5J5*<WLJ4/:>
M6RA4+ZR,>J(/7$JG^@J3<< X'/\ M#_#'Y5F&:.-7<HJJBF1B9HE*HIYD8R.
MB+&HRQ9W4  YY!J4S9C#,A7Y0S*I8DGRC)MA1E$TIW#8%:*-R0?DW+LJ9.$/
MCJS@N\X*-^V\'Y]03;7[J-6H]_WM-TD_2\87^2_ T****HLC60E22N.< 9Z_
MIQ2A\@DC&/?J?3I3/F;U/\O\*JR7D,;11,55Y"2JO)'$[;2&D"QR$3,T</F3
M$"/[D1R5!!JM&]M+]-?N[W_X8E1J<O+&]2I;=)7?G9*UOET+?FKZC_Q[_P")
MH\U?4?\ CW_Q-9_V@?\ /4_]^C_\31]H_P"FAS_US;^>S^E3S4OYJG_@NI_\
MJ,O:P_Z"\%_Y4_\ DC3W?[I_X$/Z@4W>W]U?^^Q_A51;C=)(IA=5C4'<1(N3
MC) +QB%L<C=%/(/7%/(0\G<I/.,?S/\ @/\ ZU\C@GS._G9?^VRZW*=2D_\
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M:M?,OJ/Y?X5>B>VE^NGW]K?\.;N-3EY97IU+;M*Z\[-6M\NI-1114E!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:\%^+?A7Y\\]RC.*4Z68Y-2PM9Q:A5I\]%PET;A&,8]G?DJ+>+BDT?.4N/\
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M1_P]:_X."O\ HQKXL_\ B+W[;7_SRJ_O>W/_ '8O^_G_ -E1N?\ NQ?]_/\
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MFE>W0EHHHK,Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?"/P=GC9F.!IEIX.T#X\#55Y'S-<V//&*_EF_P""3_P3^&W[3/\ P4(_9D^
M_P ;?#DOB_X4?$7Q=XAT_P 9>'!KWB7PTVKV6G^"O%FOV,2:WX.UGPYX@LC:
MZEI5A.6MM50S"%D8!'('^CC\,/\ @D+_ ,$S_@WH]KI?@G]B']GV9+ L]I?>
M-_ &B_%/Q1"< !H_&'Q/@\7^+BJKDA6UIE!)*@'K]EQ9B,DIYG2>;8!XZK2C
M/V+AB*]&G"#J.-I>RK4KSNY:R;44VFMF?NGC7FWAMEW$64/BW(.*,]QKX2BH
MJ,Y9?"TJEU.7U:5%.46I2LHN]_9\M_>C_)1J?_!S;_P4S^._BS5OAI^R]^SE
M\'EU+Q-;,_@CPWX.^&OQ4^,GQ9L0IY: 0>-+/1-?PH)+CX6V$6,L4R P_F:^
M,6N_$/Q%\4OB=XF^,*:M%\7_ !)\1/%^K_%4>(-"@\-:VWQ*F\17.H>-+76M
M!MK+3=+TS4AX@:\N+G2XM/@\F<F%L,,C_8]L?#VBZ':6VC:-I-CHVD:?9/;6
M-AI=M%8V-I$(R46VLK58[")$R?+1+4*F2 ,,0?\ (M_X* *S_MV_MLY#9/[6
M_P"TFS3?:;Z>YE,GQ=\<VC2SS:C=WX:[6%(E2Y2.(+Y:A8A3X+S? U\7FCR_
M +!))-^_.LW?1*3JN26E[V[]->;O\$.*,BX@S;BRCPQP5@N'Z:I4Y66+QF,J
MR3G.,83JXVK5?(DFURS:YY-KW?>G_H=_\&[K;_\ @CY^R* ,%Y/CXI[[=W[3
M/QH<'H,]<8X]>^*_;M&)VY7!+2'&<]1M';VR..:_$3_@W3&[_@C]^R1_LS?'
M8@<]_P!I7XTY_D*_57]H/XY^"?V:O@S\4_CS\29KBU\#_";P3K_C;6UT]]/;
M5M1L]#TZ>]BT/0+35;_2+2_\5>(;N*WT#PQHTNH6@U?Q#JFE:7#=I/>H%_.L
MVI2_MO-,-'WZD<15CZOVE2*T723=].BT/Y4XUI8C$^('%.&PU*=?$8[C#,XX
M2-.+E*4L9C*OM8PC%/GE5DU&*L[.24>6]U_&+_P=&_M6ZO\ &3X[_ 7_ ()T
M_".VU+Q?JO@Z^T3XA>//#7A;S]=UGQ)\:/B;82Z+\*/ UGHUE;6^H_\ "7Z/
MX(U+4=3TRRW7>F^(+'XR:-;6]G:ZKI-C7IO_  5H_P"".VB?!/\ X)#?LS7_
M ,/]+MM7^*?[ VAVUY\9]5T.WFO4^('A_P"+.J:7J/Q[\364R>&?^$AUBR\*
M_%N_M_&6A7/B+5/#MMX*^$?_  LN&X6?[5;26WX)_LD_MR_">P_X*6W'_!03
M]OCP[\0?B)!#XX\7?&RQ\'_"O1-!\<7O_"T[^_B_X5KH"1_%?XDZ/%HWPX^#
M<NI2:_\ #&XA\57VI^&-3\$> ]%"W=C:O=V']1/B[_@Z._X)C?$3P;XK\ ^-
M?V>OVO\ Q5X)\<:!K?A+QAX?U/X:_ >33/$/A7Q%87FCZSH&J64O[1L_VRQU
M71KZXTO45EE)NK:>XV+ TH*?;8O!YYE/^KF!R+*J>8K+FY8YPQ$H1K.5TXN<
M:L&Y]XQ<5=QE&I+EY3^D\TX?\0."I>&>3\)\.9[F5#AV<>+\_A')Z5.GB\=7
MDE6RVO)9M>I[*C[1+G<FJGLTH.-[?Q^?\$W/VR-4_87_ &U?@A^TNU[??\(?
MX?\ $-KX<^*>DV7]J74^O_!?Q0L_A7XAV$>F:=J>E#5M2\-Z)JMOXY\,:3>B
M*!_%_@OPIJ=VTRZ8L<_^M#H^NV.O:38:SI%Y::GHVJV%GJ>E:U87MM?:9J-C
MJ%O#=:?>6-W927$5U8WUO<0W%K=PNT,UM(EPA,;H6_QF/%=MX-/BSQDGP\O/
M$%_X&B\4ZXO@R?Q;9V6F^,[[PM#/?G0QXQT;3=7UF&P\56&B76GIXRM-'U+5
M]"TR_COK:U\1ZLJZ=<ZI_HI_\&W'[;?_  U#^PG8?!KQ;J@OOBG^QU=Z3\(-
M4B>61[V]^%+Z9=_\*,\17D*:+I$$4I\/:-K_ ,.&ABN=4EU#4?A9J_B._O-.
MFURSTFVTXXRN%9K.:$E6@I*$IQ37*I17*N5-1ND[6LUJKIM(Y?I'<*PQ6"RC
MC:E!8=5(JEGE7#N5;VSG%5*3GSNHJ$HW]G)4N1Q34;<T;R_H9O=-@O$EAG2*
M:W:!H+BVG@BN(+NTFB%O/9R1S!ECMIHR&>. 1!Y8H#-YT*RV\W^9;_P7'_X)
MC3_\$^/VIY-:^&VDWUO^RQ\>)[[Q/\%;W[0=1A^'VJ0R6UQXO^#DLS6MH;2U
M\%ZMKMP_P[BNXFM(?AIJOA?P\=<UKQ#X<\1WEE_IS' +9X_=+GZG;U]>O]>U
M?A5_P<6>#?"^L_\ !)7]IK6=6\/Z/J>I^"]=^#/BOPE>ZA81W-QX;\4:A\<?
MA_X7NO$>B2DK+IFN3^&?$_B7PY/JMD\%[/X?U[5=%EG?3-1O[6Y^/X5S.>5Y
MIE\+3G"M:%6*;L[J*323T?.XRTLFM'H?CO@YQ?CN&..,BA3JU/J&;YU1RK,<
M/%0=.MA:]6%--1E%^SQ$)23CC*7L\7%*:5=7L_XC_P!B;_@K_P#M.?L3_LJ?
MM,_LQ?#;4Y+S1?C)I\\GP[\37&L:G9ZS\!?'&L7,.@?$?QCX(O["2TUB>Y\2
M> 88KCP_ =<TVS\#?$+3=#\?:6EVQ\6Z)XO_ *,O^#9#_@E]+X&\(0_\%$OC
M7X=O+/QEX\TW5=)_9F\.ZYHMG&= ^&FO6-E87OQFLI)9'N[+Q%\2K.XU_P -
M>%;NSM-#EL?AH=9URWO-7\/?%Y9X?XL?@EH&C>+/C'\(O"'B"Q74O#OB;XH>
M /#6O6,LCH]]H6L>*=/TO4[,3Q&,Q2W.G7C6_P!I\N0H4$GEMN*#_8[\-^&=
M&\+:+IOA[P[I]EH^AZ/I.GZ7HFC:;:6UCI.A:5I]E#866EZ+I]K'%:Z;IUE:
M1K;V5K!'LM+58;&';I]I96EM]IQOCHY9A?J> H_5I9XKYFXQ7M,1%:?Q)*52
MBM7_  )T[+TN?M/COF&'X3P6%R7)L-'+\RXO4J_$V:4%:6:QI*%/EK*7-!*6
MCDJ*IQ=GS1<YRF]J6R5Y"Q;'[Q#N*+)*4EE::6 O-YJ_9Y!MB\H1#8@.Q@=G
ME_B3_P '%9Q_P1]_:I7UOO@*,_[W[3/PB_E^M?N&W4_[T7_H!K\._P#@XK_Y
M0_?M4?\ 7]\ _P#UIGX15\#DLF\URN.EE6A;1:6ML]UOWL?SCX?Q2X_X2:6M
M;BWA95'_ #?[337RTT]VQ^3G_!J=X.\)_$G]F7]N[P/XY\/Z7XH\(>-/&_@W
MPIXL\-Z[9P:EHVO^'M9\!^)=,U;1-2L;B,QW&CZAIE\UE<:6Y^R+&URL"06]
MS]GA_ C_ (+%_P#!)SQ[_P $T_C))<:1'?>*_P!E#XFZW>W'P5^)GV6*X_L/
M4##?ZDGP@^(UO%OM[7QUX>LTD.E:KMBTKXC>$+6X\6>'B-0\/_$;POX#_H9_
MX-&N?@=^V2!U/Q9^'A';IX/U9L_I7],W[5'[)/P?_;4^!7CS]G_X\:+)K7@;
MQSIYMS<Z8\.G>)O"NK6RK<:'XQ\(:S+#?)I/C'POK$<6KZ)J,EC=::[P)IVM
MZ/K.E7.K6>I?68O/*F1<6Y]S<U3!XN7+BJ3;:G'ET<9-N5-QE_S[<4TW=/0_
M9\Y\1<;X>^-7%<TZF(RC,<0H9E@DH3IXB'U>@U*'.FZ52#:<73=/FBG3;LX<
MO\!'_!"O_@L)/^P-\2H_@;\;9VU']D;XN>,+6ZU>]>2Y;4OV?O'E_-;Z//\
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MQ7X;Q.'5"5'$U\YH4I>YB,HQ]*<:^?>RYY0HXNLDHU,)3I4J<+-PIPJ0:/\
M4Y_X)?\ _*.3]@K_ +,Z_9M_]4_X)K^+G_@['_Y2,_"?_LRCX6?^KT_:-K^T
M;_@E_P#\HY/V"O\ LSK]FW_U3_@FOXN?^#L?_E(S\)_^S*/A9_ZO3]HVOA>$
MO^2VQ/\ @XI_](D?SUX._P#)YL=_W>O_ *35/SS_ ."2?_!4Q?\ @EA\4/BM
M\2G^!H^.W_"T?!&E^#?['7XH1_#0:)_97B-M=BU*+44\ _$5]6%Y*3IXM#IV
MFB$@3B[FR8!^]$O_  >"@C*_\$[I&)Z*W[53<>O)_9G_ "..>F,5\<_\&NOP
M1^#7QR_:0_:CT;XS_";X:_%O1]&^#7A35=)TKXF>!/"?CJRTO4AXZDM9KK3(
M?$VCZDMFUQ#M5Q'N/R#YCU']J\?_  3[_8-GZ_L5_LIQGU7]G?X08_ ?\(</
M3U]?2N_B#'\.X?-Y/,,HJXW$1A!2J/&XNFI<\;I*G"O'9*S=M+VN?2^+?$OA
MO@..\ZR[B#@FOG.;)4N?-*>=YOEZE[CY;4L)C*-&/*G9VBK^>[^*_P#@D/\
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M+_PZT/P[J?AC2M)\/'4M73P];?!WQ)-J%]I\.F"^L([V34;#^/CXO_"OXC_
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MZG_>B_\ 0#7XB_\ !P__ ,H>_P!K?_>^ 7_K3GP6K]NFZG_>B_\ 0#7XB_\
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M.M07?@+0KK2/"WA'Q/X6T_5+SQ/9>,O"ND6FHZM!'XET?Q):ZQ/K>BZWX/\
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MV06_B/P[I?@7XJ_$BST/5HI(W,^FQ^,_!?A'Q#Y4+VTW]K>'=+NQ<*(/*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** * 8[T'_/)-
MY_VLDG&.WIW[_2O\TO\ X.(?$_B;Q!_P5H_:,T37=<OM5TGP-H/P3\,>#=/O
M',MMX;T:Y^#?PY^(DEEIL;,3# WC37_$&MR1A@LDVM7J84R-(W^EH.N__IB
M2?9@OT[Y]^:_S3?^#B3POXE\._\ !6K]HW6M<T.]TO2/'.@_!/Q/X,U"[C,5
MKXDT6V^#?PY^'DE[IKD?O8$\::#X@T.20*52;1;U_F,;1I]3PHE'.(\JW6KW
M]Z]WOZO;3\#]E\!I4_\ 76I-I.3X>Q.*N]?W\72Y9V>BM_*DH]T?B17],_\
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M-0T*]LI#8U_"_P#%#_@M-_P5+^+WAVS\->*_VSOBEI%E8:Y9Z[#=?"RR\#_
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M1_:?^('[%G["'QZ_:;^%5AX4U;XA_#NU^'UEX>T_QMINJ:IX8N'\8_%KP5X
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M^&Y(_/TOP=\1/#=[+9W_ (_M]0&H?$'POXW-OXLM9O$_PO\ %-AJGCG^C/\
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MM7\3K+<.FA_$KQE8G1+:]\/VEFNK^!?"JQ>'?%.JV/BSQ;XQ\$^"?TT_8?\
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M.6;_ .N?%G#&7U)2G/*H9#A<;5BY6;4*]15)17/SR2E*5KVB[6/P<_X+-_\
M!1UO^"CO[7<'B;P1'K$7P*^&&FR_#GX"Z+?V>K:==ZW!<WHU#QM\1[W1M2A%
MU:>(/&^NVULKVL5M'>Z/X-\&>#M)U[1K#7-/U"/4/ZAO^#=__@DWXL_9"\*:
MY^U=^TIX4G\+_M(?&#PR_AKP'X#U=[V36OA-\()9M.U"\?Q!:+?S6^D>.?']
MSI^@:EK5D\;WW@+0++PUX;OAX7\8:W\2/"%O^EO["'_!%K]@W]@G5;/QO\*?
MA[?>.?BYIL=U'9?&KXOWMMXQ^(VFPW7GQE/#\MMINB>$_",RV5W=Z/)J/A#P
MIH.LZEH-PVB:UJFIZ=F!OUB%L[1DI<JLG[C?)Y"/N6%RV )"Q4(7>2V)D98+
MC9(RSQ^=#-T9SQ/3^HO*LNI2P^!C&,94FFW-IWLI33K.^KE*<U?F:44FK5QI
MXKY=C>%Z7A_P)A*N'X1IO%7SBM*4<;7CBM:\90G4G.,:TTI3NW.RY(JE3;C+
M\;O^#@%@O_!(W]L0R QA_#WPR W-$NX)\=_AE,P3S98@SA("0K;%<,OENYR!
M^&/_  : 3+%<?\%"1&#*PMOV4YF0@QLG[W]I-D4X$@.]44ED+!6+J0?+RW]7
M_P"V?^RIX3_;;_9J^)G[,?CSQ+XC\)^%?BC8>'].UC7_  D;*+Q'90:#XIT3
MQ0K:;<ZI!J%I!-<W&APV_F26LK0I-+*"[':WQY_P3'_X)#?!K_@EX_QLG^%/
MQ&^)OQ!D^-J> %UO_A8[>$KEM$_X5X_CZ321H/\ PCOAS0U@BF?XBZZ98[I;
MHHJP(&==Y;@P>9X6CPSF>557?$59TY1CK9J#B[7CHER1W<D]6]=#PLFXNR;"
M>$/%W",L156:9SFM#,L)'V3<75@\!SU&^7E4G]1H6@_<3I_"^>?-^N1B8D?.
M-N#E=G?'4'=P?Z#'O7PY^WS^P3\*_P#@H-^S?XQ_9\^*ER=-?68X-4\%^/;;
M2DU'6/AYXZTB.[3PYXRTJP:_T];B>WBO;W1?$NGVNH:/_P );X/U;7?"=[?6
MFGZFLEI]TT5\]0KU<-6CB*$W3K0MRSCTMM[K]U^=T[[.Y^=8'&XK+<;A<QP-
M>IA<;@Y*>'KTI6E&2::<XZPJK36-6,XM.2::E)/_ !YOVM/V1OC7^Q/\=O''
M[/?Q^\.CPYXV\-3-?Z;J%M+]J\+>//"%P;F30OB!X&UF=;,:WX3UY;>X$4AM
M[?6=&U"TU#POXDT?1_'&E:IX5L_]%'_@W;F#?\$>?V2' 0JLOQ[#,LT,D*E_
MVG?C.@ EB>3<=CF5<(%^7:YC+9'MW_!3#_@DY^SS_P %-O!_@FQ^*.L^)/A_
MX]^'6H^?X1^*O@2+2$\3Q:)<N&UKP/KD>IV%TNM>"]8E2UU4V"3Z=JVD:_IM
MCJFA:YIL,VNV.N_0_P"PQ^R!X7_85_95^&7[+?A/QCKWCWPQ\,Y?&ATWQ/XF
MLK&TUV_B\8>/O%7CQXKJ+3=EI&^GW'BF6P$RJWVJ*SCN"EN\K0Q_8<0\10S_
M "6G0Y90QZJ)NHHSY5:G*#2C*U/I&2BX\R^'5:O]P\1_%K \?^'W#N32A*AQ
M7@LP^OYIEDX?[-5KJCC(?6Z>*5Y14GC\2_8QG"$'4<5!JG2DOY0/^#O=6D\<
M_L',Q*A_"_[1</S@JQV:I\'6F9 ^T,8U=6 =HQ(K HY!!/Y[_P#!M=^T#\$_
MV:OV]/B7XR^/GQ6^'GP=\'WW[)'CWPA9>*/B7XOT7P3HEYXBU/XT? ?5K;18
M+_Q!=6,#:J^D:#J^HQV88L\-C,!(-C,O]B__  4T_P""._P1_P""GVK_  AU
MSXK_ !-^)WP]N_@Y9>,;/1?^%=_\(C"FM?\ ":W_ (0O-2DU[^WO#6LFX15\
M*)"(;8VRNU\9@T9MRD_Y:2?\&EG['# H?VE_VES'YJ216[7OPT:T3 B664P?
M\*]WO>2Q(Z?:?.54+(XMV\L*?0RW/\GEPFLEQ&-J.3YKQ5#6+<D[QJ*G_=6[
M[NUV?1<,>(/A\_"[$<!\2YOC,JQ>+P;P&)Q-'"5*\981X]9BJ48*,J4?]IBI
M\\8QJ6;CS\ONG[B-_P %6?\ @FJ>G[>G[(ZX_P"J^?#4_G_Q4(IR_P#!5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!X5^(7B?QA/H/A^S(U'5K?P_X1USQ)=KF#PQX?\ $15I1_;'_P $JOV#M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1
MB/ ZC/'(&/S&?\*H1::L,CR1O&K-(QR+>-'\N1Y9IE>2(QO--)-,S&:9I 0L
M;M$]T9[J?3HH>KO=W\FU^3$XIQY7[R_O-R?_ ($[R_$^+_VG_P#@GI^QM^V5
M:21?M'_ 'P!\1M4:QTK2H?&$NGW?AGXB6&CZ-?7>IV.AZ9\3?!E]X<^(VEZ
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M:HHC3(C8 JJV1&W\3[O3Y<8_\>-2T5Q\SUVU\E^&FGR/!A%4X\D59=W[TO\
MP.5Y/_P(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"L+<]VC/_;+'\GI?LZ_[/\ WR?_ (JBBIY;_:J?^#:B_*9#
CITV[NE2_\%4U^446****HL**** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-251652), and the Prospectus
Supplement constituting a part of this Registration Statement of our report dated March 30, 2022, relating to the consolidated financial
statements of Sanara MedTech Inc. and its subsidiaries appearing in the entity&rsquo;s Annual Report on Form 10-K for the year ended
December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to us under the caption &ldquo;Experts&rdquo; in the Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Weaver and Tidwell, L.L.P.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WEAVER
AND TIDWELL, L.L.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Austin,
Texas</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
24, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>smti-20230224.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSEebP9z5Z8qekhvWB3bVm6zyspvd9IcS/xtn0WUeMF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:SMTI="http://sanaramedtech.com/20230224" elementFormDefault="qualified" targetNamespace="http://sanaramedtech.com/20230224">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sanaramedtech.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="smti-20230224_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="smti-20230224_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>smti-20230224_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>smti-20230224_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sanaramedtech.com/role/Cover" xlink:href="smti-20230224.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140272190090256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 24,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANARA
    MEDTECH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000714256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">59-2219994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200
                                            Summit Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort
    Worth<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">76102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-2300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SMTI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="smti-20230224.xsd" xlink:type="simple"/>
    <context id="From2023-02-24to2023-02-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <startDate>2023-02-24</startDate>
            <endDate>2023-02-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-02-24to2023-02-24">0000714256</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-02-24to2023-02-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-02-24to2023-02-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-02-24to2023-02-24">2023-02-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-02-24to2023-02-24">SANARA     MEDTECH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-02-24to2023-02-24">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-02-24to2023-02-24">001-39678</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-02-24to2023-02-24">59-2219994</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-02-24to2023-02-24">1200                                             Summit Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-02-24to2023-02-24">Suite 414</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-02-24to2023-02-24">Fort     Worth</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-02-24to2023-02-24">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-02-24to2023-02-24">76102</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-02-24to2023-02-24">(817)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-02-24to2023-02-24">529-2300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-02-24to2023-02-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-02-24to2023-02-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-02-24to2023-02-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-02-24to2023-02-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-02-24to2023-02-24">Common     Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-24to2023-02-24">SMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-24to2023-02-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-02-24to2023-02-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
MLX)85@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "S@EA6%WMXO^X    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "S@EA6F5R<(Q &
M  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( +."6%9_(!NW9P0  $T1   8              " @0T(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "S@EA6GZ ;\+$"
M  #B#   #0              @ &J#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( +."6%:7BKL<P    !,"   +              "  88/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( +."6%:JQ"(6,P$  "("   /              "
M 6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "S@EA6)!Z;HJT   #X
M 0  &@              @ '/$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "S@EA699!YDAD!  #/ P  $P              @ &T
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex1-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex5-1.htm</File>
    <File>smti-20230224.xsd</File>
    <File>smti-20230224_lab.xml</File>
    <File>smti-20230224_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "smti-20230224_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "smti-20230224_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "smti-20230224.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "SMTI",
   "nsuri": "http://sanaramedtech.com/20230224",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-02-24to2023-02-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://sanaramedtech.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-02-24to2023-02-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001493152-23-006000-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-006000-xbrl.zip
M4$L#!!0    ( +."6%;!7/#1-[T  %RQ!  )    97@Q+3$N:'1M[+UI<QM7
MDC;Z'1'X#W4[[ML!1A1ID9*\M/PZ@EK<K3NRI9'DZ9F/!:! E@54P;600O_Z
MF^LY>6H!0$E62QA,1(]%$J@Z2YX\N3SYY(__>/O+BY_&HQ__\>SR*?PWPO_[
M\>WSMR^>_?3C-_Q?^.LW\N<?'[]\^C_1F[?_\^+9__W+HLCKOT7G]]9U]#9;
MI57T:WH;O2Y621[S+^+H35IFB[_ %^&KK^[ZO4?1*BFOLOQO$7ST452G[^O3
M9)E=P2]F:5ZGY5]^^O'GE[^^M<\]722K;+GYVZXGTV>K[%\I#P2>]/BGO^;3
M:OWHQV\>P\SQN?"?5Y]^Z&5V=5U_XI$_>W^=3;-Z/#H_._^SQ_\5+_V?,O0W
M29Z4R7CT2SI_F\ZNH^?Y[.SKF\B;ZZ1,J_&H6$1/BM6JR*,W=3%[]W5-8K).
MRO'H)EDV:?3_WCN[=^\\6J=E5.'<3KZNJ8!@/8'?E<5RF<['HV=_-%F]B5XN
M%O#Y_.K'-[^]^NG-+S]^@__]^H3MZS[P/_X&9WZ)A^7RJDS3%;SCQV]^.V[#
MCBM/?I7E\Q0?>._L899_RMG\G$[+)BDWX]'%@SBZN'=Q_ZN?DN[.GS>-WYNJ
MSA:;3SGH)TE>%Z"&?\[J?UVE9;*<1W]-5NM'<*^<?653>?###^/1JZ1\%UW>
MI'F3?F7#AT^.1_]3E._BZ-?_@=_=N[CXRF;P51Z %\D\P]LAR>?1WT$Q+/&*
M^-M7-HG/MO)_M@[M,\_C*(G>IN^3*IH5Y;HHDSH#@W=27Z?17Y?S/YKB$5_S
M8 FODWRCM_M?2_K;20Q?RQ=9N:JBK*ZB1*T ?$)6A8_HF CZD/'H-JNO(]:6
M49^R[!G0Y57/DV V%<Q[N2QNJ\\A9@=SZ[4G\FFG<7X&H_[MI^=5U23Y+(U0
M':#=&(&+Q=X6;N19]!8V602-1:F*ZNNDCJ-%6:RB&EX2U07_=]Z@\1^A6( I
MN,(GD<0Y(8LCD&/]<T6OK)KI[^FL'H_P(? 7$-UYAO)>155:P[!+D,+KM$PS
MF%)6PZ)MH@S&S .NTN427P\B6E^717-U30\A.22YJ] 2AG&C^,.'UC# 6;9.
MEC%[716.<<8.984.Y7C4E>I7RV3&!\BOBQ5PGJ=;I3@"-R_J]_+Z#[%Q9\,G
M/X(M>O[3NBQNLGDZ__&;YS_%$?SBNKA-;]*2?\;-B+(\RHL(?@F#A!?AHIAM
MX_6"Z?-RM1<*]@ 43]ZLIC!,^-0<SBK,(%D5#:[:(G(+,![Q"O!+;XL&],$D
M.8G2][,TG=,3MSS&K[B=<U2F5UD% @$/$.E(P8V<U=E-&KVFOXD"?%,GM0QC
M,D\760[?F*:@5DZB=5.B&-<H"[?7V8QG5X@["@L '\1_K))Y&D>3:>^0%U'2
MU-=%"8<$'MS449/3RLT'1@[# .&JAN:%WTVF<*":-?PN?9^6LZQ*23G#YE4X
M(U@E&,=UDE_1L<.]*IJZJD&T<;15.H,356?\<+NC\,4"?BYOX8GC$;P]+6]@
MG'PD_>?^6E8H1Y6=V"Q99W6R9'$'Y3R9?>3^@7"OLKK&, "L_C2-J@+$H@&M
M!?=& 6K@S>G]: +G;MG0K,#FP)L$;CK8V69&6_O\[/'9M_C^,BT6<,YA+=;K
M93;#]3O!P4SF=QME)U*$FL2(AB[D-=Y-V1(>FT2ORJ):@^ U5?2F@=?+I=D2
M-3K!N.\L,B#^)%"\D*B38*AQU#GFOR3OLU6S J><1MH^Z6?1KT6--Z[;?!@=
M*$]4ITXQPD$H-_2/A$:D:A'_##J'! 5_!]\@3<W'%-0;+"7I>+K2X=/CT3*#
M/4O:>C;+66%C""'EG3G'D>K![%$)HA,C.2FDE/W^A^I?5-,TI8?!QUAVX7A4
MV31;8@2I)>?X.)J$45;TC.L$M .HO&(*5R:K!Q@\+$TNXZ:IDF+S\W\4M;2I
M>S;&2O#A8J;P'54FM!&9E],JTF]'TTTP4*N \&>_/K"O&2P]C ['O0(55F8@
M_3AO&&K%%RQI*ISM>%3)'=Q9X:[>OLUX-5E?PJ#L*/!C_>H39+:*6E+-9R"<
M%+L(\W0&!PS^Z+6R?.R-5T_XP6>JR?#8@3@,VJSRQ^XUFD?_7Y)CC"3B",DY
M7.%+4%PPZ_$H+_@XJ(SV2!5L/VX5BF$%"_Q'DSE[1/<)%J:ITFV+ Y_@^])J
MC\\1&?ASS;U>JQ4F\O^<GH)UGR[G?XM>@9GT"![P1Y/"88$O1J>GDG+[\>GS
M_])A\#Q.IT5=%ZN_1=_B=*9%"<?=_>XQR.Z[Z/SL(:P*'/-L#C-Y>_GXQ;/H
MR;,7+UY=/GWZ_->__]^_W/L+_?SFU>43_5G>(<^;H7)?5S 6_=<C$/IY?8VS
MNO=_^F*&;U_K,^"2A9.7+'69ZV(=KOLR7= WGNHWY-'W[_\?OUYOG_9]XL'.
M3[2?\<W;U_C_<!'@O["</2L[+=/DW>DT!64,$UK3=LAJP^!IJ;^JA<1'[[D*
M1@R_03EDT?OH@W80?M^G=F#?XGW7,8!BNJ)F,Q"8P%;@*Z^BVT]N9Z/X+V=D
M#IS_</\^^5L)Z%"\'KN*/_Q2)TC EPU^JVR6<J. 9] LQ4@AVY"-BEW/1LVN
MW^L&(]R\S#65B!/"EP'<P>XV@#]Z&_9G6">XS\_@=-\_O7AX_NW#BQ-<-K5L
MDVB:5+1@8D?&\%P<"%MQ,SA'8+@9L]Y^&8?4OO/5HA;CJNMQAQ=V3*O&1BX\
M6&)'L"CPL3(%"P/U.EC,LP;?47G+JFL-H[&,U@7^-!Y]B&0X<\"+R(,=(F*_
M\A$"$L8L<$[K,EV3#9.8S<$Y!C]7WN@7^ZFUG;);Z.G@0\'BUGE;\8F<],2R
M%^$[^]](@H)67M$K"5&_('#8I"L)/8O;Z]UTW1"[="P!30EN\+4.3$(KZ$VA
M(<6O%?,9?=NU\59[5BXR"T?6^=#*)79UO&G:.PM_S%P8:<_U&SA(9RB]*6CR
M6Q0JYWZ!5O9NMQB8>(@[$S$:9%*%*@)6U!] \3QE2<3]11DQIW<>GMY:G3Z4
M?_-<#//DL"LK7DGG)/+AM>O68_U7S;0BLZ]>;F10?6K2NA>OX1!&#RX>8"Q%
M?;W.S6 4,3CDX*RCQ3Z7O4CV$82>=]Z_]WC@(C*OX_6A4$E.H:\5V%11,N?8
M8K(<C[P[T__F*M#]78GA$!B>$%GKKOH7';6D71Q2 B K1I"#R$<T8?WA')R!
M&(7>:N)3#NF0&.-@+#X1F'-+B:4$6N)U(,7.*U(]<2:*@M1$>[8PK=:OPALN
ME/U Q$6J U&/C;K-\BTN&RD+"0UC^,FH#5K0/)VE505N9;Q#B\A;\!3AOV7Q
MFT"#DQS;&>(F?P._ZX\>49QB552HX&=\OJ9IFO?ZVW<Y<^/1/H<NAF]=I;BX
M_MGPOUSU( ;_,4J'L:)_XB-@E_P\)FEUTJ,MC!B-1T-RY)_2%IT#,* /QA.X
MQ""/OUOD$&X-'L4<WNH_0*VSA086?'B[E+%V&X_@Y/KK@<;$L32]Y?@:=OJ#
M527:O#OORAYCZ+G]SE-]9H_-Z;17#+<<1?MW&0,#HW17?<I86+)(2+?TC^4L
M@LWQ<QF/PLWA!)K,B2SJ6%6S_24^2G\/NR%_\AI2_]9W?0SL/]KA?X( 1/OM
M/RPC?KM8\#!TH8T)$OH=E&-)%K7\$37Q*6MB$\^<P]S4I!B2^H(?8#_ZREP*
M=A'"!> ]WKH"=(&17.'UR=>8,_"V7Y)G:*+@);$N*LEZM%.NN+CN\]6NT]W=
M08EH.WGB27E723(.K5TD2]SNG+D$T4W8U\[$D_)L"8,IBSR;14^3.HG^GN!+
M<0TOP93;5!E;6J_3NLS2&\QM;2J8#VX:G&!K4?'\GB-2,>&]IP>:%USR9]D6
MI,>@$Y"CLV/O:Q?@QG@:B]$23GGHSC[]^^7KCH=U -?&!\22+QY%+]=DD_P-
M7R39I4?1?V&:'/Y\##6W \E=;*T;$(6?[6KK.H-=OEG# "_+9)K-'D6_PJ'E
MO?BUP!6^".*L^BW\RS&,?0QC?U7YK N&+SD?5]!*SQ),\#O_//2NJFN)&\Y3
MM)_ IT$WE*X83$9'\ZR:P5V&>MUE 1W*J!-1<O'&\6B2PFL1M=>/&^H&H3,)
M'>0%KI1)Z<(-DZZ2C/\"1W.B2(]H!7Y<,8]63=W 12M8+(ZE2 Q.(  .C^1Q
M+5NC87PGTIJM8;'A'8+C$O^7$50EV[AI5;L #H-I<&D]F@ LD'SGRW%GU%E'
MK #&3B12,T\V+G(#&X20"01MP4J0\QF,"1\!RZ1# 5=U8/W'(T["=_?!N?LP
M3HF;PUSK&K93\!5H_3 @ G^%#OBYQ\5ULOQL!!5E!B<#+44*&]'<%KQ'<!JR
MFVP.6UAUT#H&B &+:%]YGT 8$[*5$K:>8%PH=+K7+"-;G[[,:.\H.HDV:25/
M9]2*CS'-YR6B6^;M5_0^7# 96P<NP5QX4O G+-O\[2>1 TT*=.)L6Q=Z:K%B
MV0K,S@Q6'0X'0:[0V,S6M5IM/%3QXG#*35YGX'A.LA/S=X0[J&*X%4O=@)?<
M^02[G*$K<W8UA]<JV"$\H\,;/1[)@H'1JJ/7^&CKA2BG,U4%LW=Y<0O6]!7;
MJ%[@@H$0-D[V3=1+AN@?<F]H=' R\^@F2\"Y:NH"'*7U<G-"#L",PN'>\_0@
M)/5*%N+LP>5?%7D\H%AC'U@C9Z>%Z^% )KJYMT4TN3@9C]X*"N=ILND-7;L$
M3+A:;8&)K:IU21+<S5.K;H>T+2Q(2]TJX J!7YE($+PN*RU*JC\3X3.9%!VD
M>"#J07J2/,JIA 8\L7S.CAC=69@E N>J[U @3BZ[.6GC8S #1B]Q#Y@;?SE,
MXEGDUX57='Y*Y'7#=N+/\7@T\ZZ06SL$7*5YE>A%.L7%RCK13IM0Z@-OX1\5
M#-6[D*H#* HY:SC,/I"J9*D-D&Y6&<E4G]=X(M+W:]2 [8-%UY)( =Y@>9K)
MH3&(J5SB! :@19M,1])CU6[A 56!(-Y.Z"4Q$Y4CU9EY6XD%ZSI/EQD"3$%F
MNR(2++HF5$7S%?!DO$]%!?8?I [&K+VRR;2XD>@%AIK1(%"%;#X.L\T6F5$?
M^'G^)VR#P( )SHPR1P4-X);C75_?DBB[1W4B'FY:[N])U#$%XO83>HZ32^Z4
MQ?)  6!?WS3NL]W_9@@E:2][/M1ON,) Y750WSV<)"=\^[;RW/0MMHR]W&+R
MHT]J8A8;S(WC]8?Z$8'?=$_SU4B9/3!;X+30/5JA74;* O52C6>P7"5+AS\E
MZXP,WC4%K6;BQ/BHEJ2;Z;>+=$[HZF5RB_"37JA$"*00\?\UJ>;)']$3@8?_
MDI3OTGH+2*,G6(Y1P%1J#[HZ:ZT[()>)74O6%SZ<OE6+(T*\5S?17:507MH&
M@>N2)0>+K(51[FJR>C,O(KQ"Q HBDPVN,8XVTX_&% F,308-*X9'/C4>X<<*
M-78ROH;)3^'-[!->;QF /B73DW7J#H>*G"B,5^*B@ <52Y+"7\/H'&Y(\+9=
MPE:UFX-!EV/GGF(? J?BE#T<XQJ#QPC3[S/6_"C"I9?T=8(68[K*_L7;(ZL.
M7H&"KVGU FL>W]&YU-UYGM)Y/O'>RE595' OKG6(7#O#86FX,\6O\3/K*(^M
M%X91'.2;]H<-Q#YG Q/&HM43^ <XM"V,1.[2.6Q]K_A8:F6+YF_,4L,B<)[X
M'!7:Y($SD8?3Q*!2@R-N!+UURF'8"2F0#7GJ3KQ;A2^DNWP]CZJ,XR7ZA4SC
M@5RBY%Q4<MB(-*);\Q<8M"M4+F3+Y8$]:9W;.SG.=&E\ L\Y^FC'>3SZ%)YS
M9!UG!,2 MDJ7Z?H:@UL3N7[PE)K[ SYS@QN5\5V^2&95MD*H*9RBO#+NU9\8
M>>#U.XG5X>3TZF M2CO4YB6I4\+8KKD9J&"DK3("*:@ ]$<2"O$0+ Y$,F.?
MB*;CZMN\:U5U':H^#XJN3'_=KL&Z*U68VP+$.PY'YI_7N"N)'69&@2(.0K6=
M/'ZTOY&JZ+O)4DQ,^.UWDY7\@-<G_2(_Z;UJ^1HDKVY#*5Y$$H.\S# 6 !*X
MSG)&^Q3D?./^1DLP(, );,$V7=CL-H&GS25>KG!-*2$S5;YH%)DU,%5=K$#D
MJGU P^Z)R257"99/\<H8,10'-B-_FZYU+.+-TSXISI,57R7=B"@':&."X[(
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MRA#P)D(.:OM23S50P?4Z3#*PNPKXQ #+F$NC:&KVJ\0I%*,@^ID=K#CZN2C
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M[:E%4+<B<"/AT"6=7LYNKU#&9V!!UYPTX7\$"9X8.3'G0O"4EC?H7$L>A?[
M2L/^I:V=^?MYLN($S7JCC"D^PX-9T#SX>(6Y[9I.DJ*#X@A7O<S3&D>.86UY
M)JJ/T^OBUNJOS&Z0*\_8BM#9MJT!\*J;8FAWG7;ZO-NI&<9JXEW#))RMB/?@
M;OL6%=13&M;NCX:(NZ7B3?:>[M7>Z7U0>^;!.[!?^CD9M;^:[A1Y> Z=L##3
M6@W]L\/LCP^";3M2@;V@LLEYQ,'X+.^<&9$TA]L)>]&:#L*=8/L@#&GR>M!8
M[21ME+QWD@*[B^PCM19FKSHJ'(TKN!E"X% 9#X)T?$D.]C& T>17ZDZT7]&W
MSBV:5TY/!='2WDEZ=*+![#1Y<IN4KA'1@LIB^%9GA 3Q-";^BH?CF%3((E"8
MAFE#,Z:$(4W9PPH_;(&CCU]?/D.:52);%Y1INI=T?.*AXS;M'GNG$U1OLE!%
M/]1E#"_C5!I?2G(QX 5C;A&47'-?N%=PJ)O1JUYW:!W9Y&:?(QHL&9W(4P:'
M$8A(KDHMV*VN,<UM_V(N42>11%!;*6YR017?7$/(=YM22;SR"VM[!<)1N?^P
M@[U]>.*A4<@E2]7I<!<*EZQ?0AIL=W ?84[3:VG[5<MZU3EO \ 48:L%U3NQ
M)^('63(.W_"+2^:E0:('M%D 'J^M/1/CD;L7W)*9X;:S9JUVM+ZY<+NV7S+>
M6Y/#06M'!S$-6CN>G/+J]#5UW'%%F$_ZTVV/KH!79VV<F==QN)N?J$%D7U7'
M,2=!.8F+8T[B,^<D+HXYB6-.XF "$#<"#E4@Q1L..?D*P769.I2%Q*/XZG8A
MJ1;N[B,,@/$(H\@"]<\6\#[,QSL2!RKFV&UGL0GAG>)!6O5^.AJZ><I,H=5P
MM=4%G!0E*YA3Q%\@9W4)?[!&0JR8+5/F N^ ^YI1^8N4@LD2^ZPP?$QY_XC:
M7"7EG,TXJ9E03@'\]W@TPT98W&?.A$)=#H2G+;U3.U0^C+,S#/)D[3"89"C*
MZ%TDC4O60A)#5&MA=X0[6'FX/MJ2C!=2FI4-[=2CMI]&M16WQ$GDVI-7&-Y1
M"?U4$=YXKQ"O$.UKC+<OE-L:WR<)Y3YJN["<S M*E'I >$6[0(DK'!1UU,[>
M.01R&YJ[.TYOLS/RV$R:T?,A*-.;#'25-,<H>T/\DL+3D(!ALPJ!@4X-4>#*
MH'C'HQ8>9ZO '*PA^35.9'++U],OX*:#.][7*/62@P(U/&C;Z;G%!!JX[AF5
M&;G^P)YI6+RQUM,ZG#:#K(]10/J(KQLD?@S#\:M4WGG-;6-\DM,0$FIDN"&P
M^7A$;WIS>G^0CB4H >_6)\?1WX6I[#D<R++A4J#G9X_/SO& Z.,'BMJJZW3)
M0$A2.JV8 G'#/[CW<'!LW*!3514G>\-GLJ]:$[J^Q@8K<*Y3O!^QA*V^QH ,
M:(ZBJ81Y+8,ER4SWK/;CI!21MM5_E6O >)L4#2E;&'1@;\VOO6+?VA4#>>VE
M^MQO+F6Z6 KG'(8PJ.--):3G:"DH6U#_3AQ5UQ<TD<E[5EW4L@.C%G 9*6=D
MV!-52<M;1H>50->L2:Q?ZM+1LO!B$AFL_:_29>S"8%K]R-DLWWV*S,RFQ'I-
M-QQZK#.IMR Y>%(, -A&JV])8:7U*1;-E@U"V\7JB\4&I,I2;P]F:%#3T^AE
M;E3TTGW7T.O85,I;Z!QGG(EWIAD<7<G;L>TOA)P(>"ZU.P(^%XP(5@$\?U)T
M#\_/[TU^/YE\>^RM_B5-9+)Q;(4N8O@T721HDTOKI ^H;9GS$["8('?F+!@4
M7*S #,I3^#.U+5@0T+TLBUN,GR/[!3<<R 68QE718)#F*8/&D3NGR*].22"I
ML*S2OG+RXNIC*?TH@7M7X!%>-8+84L;MWCYH]R?)"0[I_.%D?M+NB49\&^ ?
MS*0-AC9[X)5>XMTX;$_QM&>"N1>P/F9U0_#B.F&H&*U0FG/]1Y:_$_3@O+U=
M:VU';?J44+[UH_8Z^JBM1O3^I]GK(Y!_*&A^_Q@T_\Q!\_O'H/DQ:'XPML6_
M)&@N)-T2G;ATG$<?;F#4R3OLD\IFNBI]_4GXB6>:9H<YRXU.T0&X%7==!\RX
M1$PLFE&MF"G,%YO!"F1K4U9?4Q) BN#(R&YW5\*;;H'^Q4;-:-_%0IN\JAG=
M%RL ,6^UD?O%Q X" R)LAVB_T8;5J2-N .%]@_<=J;#X(9DA\10Z% 2_I992
MI79FVS9]19K$+K1!.PG[#>LR,Z -WJ'^_74P%3NO@[VCO\:)3)*$C_[CLGB7
MEM\\34$P2M@O0;]?9^L///QHS-K>JK8['/5*$\&?THM%R EL(7^8TU#TF VD
MML(F YW3I>;O@'C6UV717%T'5BSU;EZEBGGDQ!!EQ;C<VC<<E%:+557,,BIC
MX* "^.:KJ1^XGY#YI'P7(_>MCT]ZNM!4:0WNA26AUQ@,NA='-_U+FLAD.G5^
M.IPBBC;UL]-R5HO@6\U:<FP<!B,6EBNJS*?8EPN6\Y\5]B3-2^KD/1/0N>9#
MV"\26?IV!;+:+2+;%\%1L+Z@B4QF,Q:LM\G[M(?PV!$E]%MB-X[)'B%X.XN7
M4*C*M&[*7.'"OH[-MXL.&/*Q/W:2\0MJ'&-471>WVM@]=\K6A3BU/TL/N)_;
M]-)#Y+VS8@5?:U)'E<69%@+H4>^$2I 15T@-M4B(C6 ;18XP\S/F<W.'*C:/
MX/=P7(?EIT-7=-LYW#%'CX!:V %7D&?@F/.4$\:XY#RRY:8+S63CM4\4=#=Q
M99E%8I^0RSZAF^Z:C4?#$;A.45L/11B7J@2DB^&RQ$*ERMEX*O[@Y*B;)*X9
M614KZL8&4W-EF"'^4^' 2DLAR_*_--[T-4YD,I^+ALQJQA&]3D6M<8OC+:5H
M']?FIPW5'H^ZVO=**>M6Y%PSU(D&BL#H-,4:\#4/FVHLX85DTY:I+="RU3HK
M]LW<@YD)I];)$XQGK1-W3_AP:K8NF!T'$;E^)QY[SMK(UW6UNXCW8L=A.$R!
MA/QSBS(5*!62%RH#&AA+5+:<SYK5E"D-Y4-8+^![K!%\;,492AX?>B-S<%U1
MP>LXL=18BPJ\==305Z6@#U>M$.S[5'ZO*#.WHJT6<W1!#2A?\4? D_\T./)=
M=]4EDP,MA7,G% 4,S'^T+%"HO]-F;]L:@ ]UG2Z=_(Q''!DAZ<4MY")VMF=,
MJSW-*01[S'M[B7L;W6%K&838WEF2TJU;N\7=Q9U]?&+,"*(N<_NFF[;'=N^5
MT7HFEI[XP(Z7<=&GCL*12M%(U=OV@A@-/ 7&>#1MLN5<]^-?!?FCW$P0?G[1
M[BZ R-"J<KSQ?F2>HS%;L,43&'U[5@)+ZZM $I$Y;9#&HN#9;FPP\:,/G9.L
MX=+W3ZM-^H3-E+42"^T66?F5PAL=!;R=Z]!1J??"(QGQ:<G$F,R;6D F"D8@
MZU)D1H(RK@5E_ &BVZUP1!N2ONI(TLT0R P.7\^674!SWF5!"65E'T&(=LD!
M*+G/(PC;^!JMS--):@O]P5JS.[*G#X[9T\^</7UPS)X>LZ<'XW>FJ3;7OLG*
M0N]*WY?LSW(S.PD7, ,&.*O4)M^W79?& 3L6GMS:M3;-6$@7"&D1P2'E18K>
MQ:2=KH2[LZ@D_#8#TY](S'4E4K]XVI?)_X9I6Y3;G.@0WF.-44!R?IM4Q/BZ
MAB/9U FUO2^EL <K+/ 7+8*3(/G:OWTV!?M(P50WJ2U(F0\Q>B=4[,5\W>.1
MH\QPD2W'YN_39&P&K21=;/:J.[H].68#/G;'-+^OX+DNJSKOH!@GM/\2YE5
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M.E05$Q5.A"?4/6R/C4R8R8YU@BSD#_?@QPV65&:%ZW7*E28@*D9Y^#51J5K
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M2-$@FF[('1?@=%!HLQQT@K#(_/C\)VW>].,WSW\2^Q\K0)6#Q[T8<UK)DHA
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MM%W\!HW,V>K&,,A"I79#J*S]W2?;Z+PJ_),>";O<%[@Y[5V)W*:P-]>S*W1
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MI8FI8(%?T7H#-X@@%-T.92R?ZM/)QT/S!4UD\OZ]0BF1[(0XHI$AZ&WR7LL
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MG1;@M+YUDA.Y! 4_YMD5M>X,"G#3V75>+(LKL&R)YKFR:6S<T*8FQK!J5H*
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MF9F[=DV!"B%=Y9M1K.&U!=WE4J5F#6Z+K:3X4R=V99LQ:8!4]: H'I:JP3X
M)OF+"C K9\T*LUUHRYN$C+R%70,A]JS0\Z#6 U:34@.#\^\NAE^)4 QIP(8U
M1]B7I-666V-OF*HP^AI,^#4Q4- Q ^V,1:0PR-P11 B(UP&)59WV[UX<F9I!
M3YEIB:%Q%<D"2XD-U]E&C"_62X)&KC3>L,/?%*5\E.H0N:""B 3+]E ]&%G'
M:@2@]3I*.2\$# Q?KVISN\CKZ;9@0*U;A #SO'U)\+-F ))R3.;S3%+5 5*B
MTT^=-@[N0C#J!+6-(P]:)LDX8[^=Q%#KMME9BR;3*[.-PWE5X<2J[3,CC[:5
M#W"=%0??7*RS7,K32.;!/$BK2GLM8<6^H$MZ:TAMA9N3VLXA#@[JY,?G/VE!
MZ(_?//\ICN 7U\4MN- E_^P\;&S7B-@@N74NM>D6L:FX4XM2XMO<E^R-!T 5
MU_MKNC25'NBF8Z9\XXM:N7$15P?UK)I&C>$=&W7&0\NHLJ8192K)<6\Y%T*;
MV5*:?>NR:$H\P*UU*7+""8"!9A>6UX!BW*U\-2^&KF:P@$@)BL4?:O>A+9DF
MS%A#?TBP9E(U73!FK)53FM^!DYA) 8D6=H6[XA(0=(0^U8F>2+(=CW6_RB-G
MS^D\-3M/.DC_CARC</B\<2?ST?N=)E]2%V#X^'K#[P)II&H+X=?7"AIX F\D
M[A[E[,TQE6L43P+>"1RLY4/".ZC0%7Z$KUIRP(&"Z 78K;X5BGU^$^S*;1%-
M+DXP2TH7Y=-DXZO\/NF!Y5%0_OWK/K*//NN9;8T&_3FJR'+QA"KPWO8_Q2=.
M<()3*:T3W#C$>PNI+43R5*9%Q&7C7+L)6@&Z >7S615ZEX/6B#]50UTO@Y/O
M8#;L!&._-7_^/??6399$SY[^_?*U5#]E-STW/*=$B:EA0"<1PT([ T_S\993
MRR(("M7:3/0&'>W)E&$MN5W6Q8/)]$2/56AMXK7OKOE94J7='>@NL^B\EO'W
M$>,?CYY)TA?'%*L.<^(B^@L/GD3W")\X3VV,"PFSLJ565^^^%GK&B"7<3LI-
M<Y?OP,U!!R;V ?Z^ %[7,.*0J/^MZB]$A.IQ(X4!PK=L*B+(=0U&Y/%P_1E%
M 49VK_*T707 R4E,3?7@_;IP.V_&^'LSOY+ST07L2A$OY1'0<B*L=EIUNQ)@
M>^PBJHJSZ#=_T=->"F&-?M#H,%^%2)]>F49 0><7J98S'_5 Z[CGX4SJT_*6
MA"=@Q=>@[>MV[.G&"?N+8\+^,R?L+XX)^V/"_F B@PZ8IC06QA9X [L;O42A
MJ7HZ@Z(-1<&#U"ML$Q!)*(B8.5:%RM0?LV%;!70&9&#&5 )36^@;&7J:P_._
M[L2,?(\7&#1)NK(L*'K31;!L1<) 4,V-@Y]AF_+^T< 6:9W#(" /#=1.VRFA
M?+&]86+I*$-SYI)MN3QUUDSOZ<K-A;DBT@@9ERMQ\^%' J76$);&IF"+,,4Y
M5(-@"AG >+M1^(+? K^R>,7/F33'.RB9P.>ED#\3;M(DV(MK0KI/I6/L? ]A
MVB)+W%1[,'X8=<*'.^)J4?OS U&Y,*I(X>P=;>VV!A\=J$5IJ78TKMW^-$RS
M!X\;"ACWSF1'?[Z#M:^^QHE,!&3UE/,DY)#[K7I$P \)S3\AATWT]],/R-GT
MRJ%)V2@-X5US-NUZ&R?_.\'.\;9\SWC4G_")/GF^IQM00/]F(_F4A+AXW>N%
M]U [7&9.:86OH<PZTXVA%X;+@O_-<F:V8OB+<Z'IFO!APJS4]<0LS;Q)J0A:
M"+:$^,95;U)_5*YT 37[7JJ+3.F,;^G92LYQ[&"HB:%1PKK )"'BI%?1^7UP
MTV/\SPS_\P#^]W R/VG536CK-JE#\MMB0Q!GT?/0G\60:*%D1:U:(%Q5]I0'
MKH"./#RX?^_QH$#$[IJ]P^W*$F**G]LMZN;"(J_"4V6U1G^KK6M,75B1"-2/
M7$1E, /)1H42(^E+X/*FUJXNE@8OH5 :+;8D?=GF8 V"Z\PV0X% 2"I%2+0L
M#9M5NI:*%H5)X85<>P]1X"!@-.*Z.-^ %S,199-ZL:3U\C6+"^WI"+OO.M)V
M/N 37QJP)A//B;JTV"2F88Z?+"FXK/"V(+%,$TC?9T(?B:L&N[),D[DV#,AZ
M%TPXC.U0:!DZL<=]LR%.L+R$M&6U)[TIIE5?R$7L9H[Y;0NZ],M#3ZS96W+=
MF>Z=]AF/)A)&P^K(O$I;X:R3J"H$?:0T6XR5M8_KAJ?:P:E=@;PPA_%)(WEV
M-KL">>$P/G$DKW^E>@)YX2B.D;R/B.3=/T;R/G,D[_XQDG>,Y!V,3RBU!R_8
M(.G3K.P$OH)KNE2/RP/\T,XLX8[Q7^*88(_QL,/B'8^LR9MH;Z4!RODEDE6X
M9)V:]P=["7R-$YFDW7##%G85;[$-1(T]\L 8"$H"H3#W?EMO/'+&WJQ8FQ+@
M/6-=MML-C&0/O*3'#FD; Q]49'3@WNB]MMVNA5_#V?@]0;82^=LS8M,!V>Z#
MJPU7:W#$XU&/2^ FNB<F1%><S&4":!#F 0N8"H4H.,R3\-BX<CP!S(Q'?Z!?
MS',1&Y@%#2WV;HC%/%'#RL3/FO1"CA3*R7'K954XF0ZETFX1T@3A7+1R'J5!
M:AL+W50&\0Q%?R6$A5"$1[VPI.V@ [+.B0"8:QB]-.C@ TB)[442SN4D/+GR
M Z@@Q@+#/-Q#LJHOE'  .O%PE/N"E?LSZ9/@M-6 \J:P">P[DDJB0^]V%SF'
ML8Y.L9/,,U'98VO.:AQ-FUH38A0_8LG$!(8(W?G#: 6CO:XD_T-"QNCQ/ER/
M\(2!;JJPZ!B.?\DMR5"'\-R\?TM<6Z37HO.+4WJ-:"OT:)/:Q8FKGCB= H[.
MSR<)7PL</W[X?3]\J^>P=@ZGML!Q*E((D.1HJNOM9S"TW.%IS(Y'\,N?R.2*
MC^!O;.:\DJ:A P=0[>E?X>+0CT9]!'C&U)#?5"*XJ;9 $>[ UHO/A"SP );V
M<&3DN@W4>$G7\QNT&%A2_BD4?:RPT,E###BH 0<>MICM'K\NW]8BEW-SJ)?
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M>FU2__Z:&(3_V$/&]X-Z6K%ZFY(ZHU0X5PV [%*S]?-[I__)8BH?3?*\<<V
M[<?^XZ[5 IV4/,?:\F8U]62)[2F-1Q0^K*_+HKFR!'1]/!BQPR;G::VE="YA
MIF-SS=ZW\NVW+Q[K;YE+O$R7Z0U^3)8TZN5QB"YY%5]W5S&V3Y/,Y@8;WIHP
M);='IT>,1_(,G>FB0*82__J%HOW=DT B@HRA)WIA*@\R/]8^E;2=FT&J7UIU
M/>MM8AE 4WC?+"'&< %&$ E@&D(:?*$($*E^J?J@+2SZ\MZ>7 C&RYB<X@Z3
M]V/U5!_CT2#7QS#NAEE),$!/>"O9"G+P.RL$8AWV &/%@!3;:;O[5XSE41@-
M&)H3EH.D1*]27P<,'TZ2.9W!*Y:LBF9@4_O/9:R9R_'HU<#Y4\E%D'F:5WQQ
MKI,-W95=CAQ_Y-N9AE8>0<8U\88D8_D#X5]C-+<VUD-K8W1P6 +6:7_)UK,P
M%MEAXO7*>((-*4U/>"2$/<+1ZHE,WIV@_$TWSEI0$>B3NOY^;4&E%!\,*:>I
M>&F,87)"JG$\HE"@)(VD9[13OQ[81,+)^*Y>*=H+Z-0XM!/U-G<%!DGEJ!EM
MPW>_Z,35XM=<-5KW90=KO>R(8CT\1K$^<Q3KX3&*=8QB'8R?L50_(Z #1VNB
M>A0]\;$;=B<FYR?12PH.]0 4MM45< [FXH3O"C;\_9WY[R"/_AI<3_>_\RS_
M]P4YT3"NVABSO:@U$3K?H;RU:((A<]L]':XCS,(C$"G)@T)"FYK<#D\XV0'2
MO^/,B&QTE292Q8U-D.M3SY?LZ@4PA9S-W@FAI9F<)HGM8SP\7C*O'GU_9P+%
M.\[G$-38@1X^?_KPK P'7_H)$X*"#G!,W.>_N:0H9Y(10$VJ\@G2E<\Z'<)+
M4U</AW#5HBE'"J&L:*KE1H(_[BTG1\'Z<@7+2];N$." >"%$[;C#7^H.WWC5
MX6HE6JKC>] <>^L!>VO;WTLLRA4N*'PQH(-Y7F/G^XNS>Q>H3[X[NW>.5YP;
M!!N2$JK1 #62)-NX*SXC^K[]U?;E5J:S95)5 6,;9B 3),7&CO)HT7*8$-_#
M $O$CVINJNH+L+RQ/"0_N_6YG&'Y8BUU--)M_=?B+#I_\.!DX-2,1QSN4Y/9
MQUV+G,,9A:?;]D: ;:F%6:PE%MI6TH6"PV[$>^P8;%M1PA[[OATM/*KK+V@B
MM2E^E4UU=;0N!CJ1HBJ;7V#)8&%(IL6-\)1GEK_=5#\J7;-&T_%#]GB+?D!0
MM7*3N[.75<XP.)&4K<WVDXC/Q5CM2)]+C."[F 2LF3)VPHZ/ ZD) C8W;>[R
ML(0XU@?47*&N^%!1#/0:8ZST(PPZSUP5\PSYPRB%ZEA\8M)JS+^WHPA88\@A
M'9+JVA81$N?K+(^9T8OAXMI(<L"*O216;*,(FKK S9S1JA#\=.X8$WLVQH(-
M8?@!4H6CN7G1<>]!.JI(V3?)9'SC@?*9 7]*3SR%P?(H50U+ PJ*T"?E,F.<
M+(TG:()GH^T2O\97P.HW"JC6MFF:UNNXI[XR8L(C(G@G\=W 5U"7NS2:6TJ%
M>&+@NF_I3DS*\7WM%Y+R=)UUQA=ZNJS]-ST:W/.,6T3('K?YZ/&@P\I(!T'<
M.#RS"L/50Y)>%01SR$*8L6__0TICELV9TH$*"7KH4!4TW[M.U  IY!*BCA%S
M3>:I># RF%!,;D5:*:"[+!#E:7+;:D->/QXY,6(%Z$4IVBE)A6W0A^M1A24Z
M?4ED2<GXU\11C\;?:\J,:4'UAC!XR0<-" AKY%9+2:/W[W2"$&(L[*X'<.%^
M2.[EVV/NY3/G7KX]YEZ.N9=#L?$G*^%P2J_ F7S)@-E/E6<1,,<"0]*3AZU&
M4)K6#^_F@1I.;Z.XUDD.U,#VLV((PHO)WG=]EY&W?\"@E L_JP(L#6%BWFL,
MLUWU8K%>@:W"1B5343$LS=$JA-:^*YG6UC#4;SJ]2CB2#Y=;B0[)>*2XY47T
MCV23"QCD<0$N>QS!^8\F@;.M WG"7D0'EN/QSTI_-.SQ&#0-N6!W<I>V>38?
MZBUM=<$&W*7HX[REVI#'MEVF1W"$]N_$XRDK!SAQ@C5;L9F(B:<\I3/I4.U!
M-(QM-X/P4W'R%=G%AQSFN(MX#P[2B@_2&@5)G!8B0BKIL@V6I=O"+,.JP[1Q
MD!H9<R6.D*,49P18-G-5>?UQK=C)\BH!>[H;K!#354[2I!.?XEJWZ 7]O7UD
M',^)MH6S1$T":.9V<(DLLDS'6?:&^&I@&5VY^,H!Q!)B2$;J9T0M^7A&4!*N
M,Y)>95SBZ_FT'4-5,*Z^OMR?/I[0-O651[:UVB<':\!_C1.9Y%)85*P0F&E.
MQ-$N^&1V 5=;SU.NN\*0*)XV(3& .<PH!R#!?5C257!)J.91PZ#BWG=M(Z"U
M?:$-T-(F,E#SE8#20^-F/(=5FM;MJ!&BXQ7+ZYI;!NN;T_H.T5-E"R6Z:U73
M#"]BTAXQ65M.^;?-+<47PV4^.;_7%3V[CQP[2TT_&E=F%G!@E,)&SPOAH?-+
MUT<G>B+9K]=;LU^>.KX__>53Z;SN 36]62!7A>.> _OB;H.3L^C2=7,AGIT/
MLPNVB34_K%^XD42G3[KCZ)=D"4;.XR1;IALT:>->@3<7>$?@@R=LE7XZP#&Y
MP R:689%(N:;/-4M!ZO:ZV3UC6T\^K!S%NUUS%SIC1VK+S=I20N:]G=11LYZ
MH*["/3[!L!=!.4.,&&:8][ERMM0FD@;H=]2+IFH T4RFG]$ FOX5/T?%UR11
M7Q+SQ-4U;,WC(BF5K0*/#Q-%> #XG%)(E/@J<FK3J7U_%QG%L_U'W2C;_6?Z
M3SIUK"?K'GZ!FT9-L."C)=SF 5\0#QSY+V0;54YGLNMR.6A*'%Y+)B@ZG9RQ
MZ%0C=I=;(6_8#\%K!&-X]IR0Y]19;+G]$'(5@/!B-.NYI-'A6?U?=T69**M^
MN4Q],%4>$S&3E!XX;KJ!)UXGU!^#OG*%G=I<_)\.+M5/BD,9^)/>6'85'7M;
MR[$UET,^7W]?]=CWL==0;.B;=G!6NU ,WTSR:%I_01.9%%JSGZ46R/&2BV[=
MW=V+>[XCD_HNBQNMZD&3._I<%C<L!TQPI\D=_;F1.+AV@@&G[^'J,';HP'YU
M>JC8_):Y)NZ,-'!JA4;W_[?WK4UM8^FZWUWE_Z":LT^7J5(8+DFGTYF3*@=,
MXMX)9 .9GCY3\T&V9%!'MCR2#&%^_7YOZZ:+#=T$C*.JO:<#V-*ZO.M=[_5Y
M-O8(KTAOO6S36P^<WGK9IK?:]-;&7+9SOFP_<C-H'ST]\@9>D\*6""3=<:>Z
MQ=/[V  .LA2MELH@B4H/6XKY=@LC<"5FDK+@*XB:28FI#CG?J+XA**BJIXB+
M1<&U'&S+6A?#B%DIQG+%FH_S70<WR2A.XO_H<GE8FWBNIB,W%/CDXTCS^FH4
M[Q*6'WK<P1@>5BB_E8LO:-A2AE%&L&,/B9 ^1S$5=M',-,:C"_4W\Z[B-)&H
M'O-ZZ(7G[S&U&>8[<$1.6S8E!D"'CQEB3[VBF<&@U)>SV9?I4YQ([]]\1(<&
MQ]*XY4V4 (*YPX @DTD09SK)0:TBX-%FAIO/.D@@2(M,ZHUF44S"$6,KE' K
M8QL4/!/I;.,P!G\;V\4%*)_P.4$:(Q=!RPF<+05G]9UTG_*SR1G41>PVV.98
M;$KEO ?21X\OX8C1A-"TM(=;MX*ML*_11'J9PE1'_X&CU6>@.%G,3XRN@O];
M0?,-CE&67O'N!^%5B:+> ;;@L*G@YXR#.>CW F0=Y<Y%Z/;UF3!?FTD-GGJH
MS81<R!,4,(4#=>77ZM[:8:!4;QFR#Q\9!Q#1*IH'")42+(K+-(-E]-6L^3Z2
M!22MH''GI]/%3#5>] +GD#"$R<Z+6AB4;@<.RY9[1$=+F)+\ZLT=E "Q/7-9
M:8U@?V:TJ)9H<G$L#; ]N6LTD5[.)_<M.*/>V1<^7'Q@_V<!0U'-/IP+&,)I
MQKQ6Y>*Z)76SSX%9W1%D!%"5X8#X_)O>>U-O]Z"AI%N5%;^Y+VU.C,-(/#5?
MH^E<6U:U3^)SH.#5Z5%I$OJF^M_&'K);HI/@VD1!*/^46Y'MW^%C>2CHXUXO
MA'L5>Y4)]!&<0MC;K2ID'!O4*C!;(*5R/./&*GK+OYVMD(B1S-"&?V8STDM2
M7!P+#$HM0HB!W'BTL.WG*K"/M+[,4DD PK<Q&YOGIF"'D+-TQJ4^7K7UAZFU
M5!61$W]#C<7XE\*9I,DX2"UE5\+F07!D>2XBH82)N+1E SRG'YP-%=@"$*2,
MK"VSU0+#:>^IAYO" 3WAGTXQ_**VB M%J R=D<GA5$3)A.RHX&L@3]"11^I&
M1U'6$(3UK_3*;]3(W C<IEZV#;82ASSKOUZ[W2:U4)X%BU@-I!?!>;DL2H*Y
MJ'I< \VQ5L8><DZ/,TQV +E;I2KU9D!T2<D1HL(P?I-OS@%7V'^3@^#]@7/0
M7GAK-)%>P1?>69"- CAQSTZ^8N*ZUB=3AF;5;5+ZF3[R)8KFF+)<$,KH*$V_
M*,,16UVIP922\1S=CU'AY)$Z,?I)1$F.S"]6%I@H1]*$M8+R_ZSHBVYCL:Y:
M75J+GEB0674524SA% Z.6#44?&C5A<HQ%311M7%GLKE6\=V$#J2,60'>UW7X
MONOW/PFAI$ER(!_*G&Q(OCVI@W@<A8M,M4MBX&G.[<7*"Z6UBF:!E*ZH]54U
MES:B;03?2_2F)+R7Z%"374+[P8ZMC4]+XV"VEEB#HI$A0!M6R8E0@&CI%O#]
MYKPCBV3@-9E71LWSJ.:UM =U=3!X 6+@GZ[(VDUJV Y?<M,T/ *TGA?*K*!6
MPV+!7 QN)QF.?11Q24^HNE^K;P Y!?<)!Z!'J@2K/ /%&*+3_,HG"D3-4QH=
M&^YO*>E86 TO5B1"H ND$U<1^X!]I_VNT*:/(.^,24BT #0L/#IW)!#B*ND,
MO8'ST(0<[!;6;<Z==0VW4"J50,+*-J<Y.BOAE/GDV9>RI"QS;W]GCT;Q:N='
M769249(&^M4N&JS';O0LNEJCLNQ0E5WM4";5U:PE)>]?PVBRI<'/*<@FH7H2
M-(:(\:4!N85 4OG\^<I8Q'_FBRG<32P5VI*AJB53A<.!,:K:!N\>+#BVE>2O
MQHDV@F+P+7&FJ_?'WEYK7__4"A*JTFV7T+O5"J)BG2X8R!M':N(3)OU<.31&
M+UC+H.KJ!%:;T].8SQ>T;ED(]7=SD.3O'%J/LAQE#_Y+W9J(;B5=%Y/%3+6!
M!A)=@J>I^I8 FVF-FA@+-:G1)WI-+>@,\='L;=#'WMT/%T!#+;_8H/9)IR9O
M4JI((: NO"G*/AWQW$@AGM](^)A!@ /,["&*.4Z@PI47.S"ANM] F^E:H4M0
MZKOM-_VI3<@_<$+^IS8AWR;D-\:K7(A7&8TS<#VRF[IZM]?>$;>*>8<"/A08
MRHX[EL#5%8-)A9I;856J5S/UPSS.<IZ<N2\*;E5 .^)&PJFE6_EVY6'=#K_[
M)N8X##R0894B>UT4ZE2=KR-.%O[F[8V*'97_+A\ .RE-%H[C1K7.E/X\5)Y&
M><8]RI%ZEE. Q@RF732+SY;^J[I>94'08I-5YZ43 T1YJ&X@B!U^_+KAE6P(
M/2F_AS\]&R-XN% 8X6\4DPG<^.C:FJ$3]R$5^)7>K<UV,B? R]7P5PXI"QF*
M#OL/D2'?L:M)4(BJ$NH2L9<$E2O*Y818=I3#<\1+8T:_A'W%:\E7_OQ$[G<:
M/VV3EOP4W*CVG@'&&_(F3B^NF4D2#DMP? GQ<2R,3/? U9("5,H5M/.!0/U;
ME8@7MSHD5KM%?0F\[<40X0D29Y3CW79FU8378H[O80@-0U%9"KZ3[J?5Q]QM
M1(4C?A%3;Y-D;RGI) ?0@(>ZA?>LPHK4UW4D0D3@'!QU?X#'80-Q:=6K!TR'
M3XW2.;T5;2<#P?;GPN8CJTT.-+!'J4R?3PSE5!+E2\;/IN:MK%M)G=J7A+71
MUD.<><E3;*U#H$UXW1CPGKJ$HLEDED0C5S5E4CN $4'*E@=?1:5129C0B(8+
M=N[R(IC.Y2>+V&W!>?U4?5UQ>F@:X+NO4*6/2:X>$FDAD1TMLES"BFJ%!)L
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M5:8IZ/0TBV'5]0:%T3@),BE@%)*SS]MGV]Y1A$D\.D!XK_^69E]4YZCT,ZF
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M5[L_MB['^DQD$(PO%1Q[%3<.*]RD(X^[+\.06(HF::8K'A "45 ,%9A9($2
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M8N3T9]U.9*Y$UW#H.9J^<G.6U/U6Q= HV323NGO%P$CNERLMK7'1':=,+--
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M#^/ ?'MV.U8'ME$TC.JB4-(589R#V1AS,-'FOO0UN60\NP*Q1WLHT61%BYE
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M=I_>-/:$K+QO*EZ.XG QCI$%^302E^4RGE<O4*OZM')QMICI:].80F3GYO+
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M82&V7O-=2-W<43)YYDSB BRC_] JO,;O\!5'1GF*"$RP@H@B@0 L.259W"P
MZH>+%+/$&R"-C]U4\$U/%Y>Q-!9!U)\RW.G[J8LHU=]T._4%.+W=+0Q7W;;<
MI5*NTMNC[^L:%(I>Y9?IM1H?EXE8GY"")<P>6F"6ZN,*C_!2^Q!VI48OW.K]
MM"70V'8^Z[;C)YB#WCZ-.?H*[BH8FE3\*\4;MD%JO_0%O704C8,%8DMHB V<
M5QCEXRR>*TC)VI1JJB%!=/:5 W9I1/54F!DCV L^Y S4S2D-K%)& Y@J@F1I
MJ'&")YEFM]\\0>QN6C"L\+*>GT4VNE05LRR3YHO:-;O8TL&3"+'\%AFARU&G
MQJFIH-X$+;:9QL&'X+J"%VYT%)?')QC2<TJAJ/Q(60BWL@KP0D,80.D:R+E7
M(+>Z!^#?%XL8&VAF$9;_A=$8@V_<0I#[3D$^-=?</,-AZ3'^#D-C,T5=W'[)
MD(#!T4^P+OA'8S7P$*WK&YYU0?5C5(884B*<XW4<!86Q,0P.C8XB(&@P7 =X
M4.JZ'?+E[0Z^AMMDK'[N#U')>0[CD>ZPH3.E>P2%A7L?%)X[(0;%$MVAPK/Z
M%41+9!Q'>FR,"1<I-'B-$9^;<XV-;$Z>(8M4C1F&;6&APPTQ6C;SN*/B[G9V
M?WRN#KTV,"H?\W9?[MWB4\]W7MSF4[N53W4[-1_;N\W X%.]T=9M/KB_\[;R
M,93\FC6!VZQLJ]%YTV5,W!K4WG9/;")]Q,?,#*1P%4,3F5(T-2Y=9@8ZT,4\
M9+4>(SC;5'*F8O:*0&E$MK)0"@1QJ&4?E*7\B=ZH_J#T^BGAOV;\DC,U)I6(
ML6JL>^KZ4U>.GB@H]21&'% $1BRJL/!%RC>]U $*TACB/%*1^Y]=$7ABFB$D
MHV0%]<CJIMCM+)EC7;%\>\36:"*W.F+-4NV795KJ+P,%6>IQGZ<T?I9 P76D
MQ,+"-8VK-O0WL2$V>TVV?S,X?-<_?<T=H2OFA4.I:64!1]PZI!;@=\/GG6)[
M:66J\[A\,KGNX@MO*0*@Y0NC0 3OMD"B?%8MDE)U>A-SK0A5WY!9+05/3P/T
M-;)V$D]C3D1Q=8'U,-\$'8(Y6LM*FUJPQJ">R.[/F6(IBTK%S]) HCN;J'*+
MLUHZXN?-M</?E.IR^WX610X>C1+5SS-BC2+!;XV$6TV$TSOW.>9_HM$W?*,1
M)N"@8C+BB++=.8+$HPGXKZ<UJ3^08GR^TZ88'S;%^'RG33$^3HJQ33)^"^T_
ME%B0L<# XL<8&3=IY%(0A!]QROSK&GO<@E4P?9((C?T\I4*Y,=Z]XC;D<[AQ
M3?$WE1LQ+2=Y'M)+Z7,OII#7Q-B41$CM%=2E0$?>#.+\RO%M[MUMU(*M!LIJ
MXLZ3=;1$HS;Y"YUC2V?<_@4UVN4O2BL8C7+;YWW#=0;]989U<(++?/S__K)W
MYS6]SR'^/<+J6AQ4D2&@U4T*EKYO#YE4;KLYZS'$=C,>;8AG_>/^:9^']7%P
M>#XX>(_XHMOKNCU:\[Y &^IAMNH/#W'M1_C\6P_Q(41G'H1H[F@7CIPW'MTZ
M'?CU&^W;FY]E>,L&O,I!?IRQ_VWXYJ_Y7T5OQ>/+($J\PVWOX_@XBA..>:RG
M EM3E7"?PZ(PP2TDZS'&)K+"8]$"X[72\FC#.D>>X745EX/+.)KP2(YT_O!D
M,HG'R##7RDP[K,>W?]9CIFOGV?0/#@:?B!P"!Q9H-(T00V^3.,N+9\$HO=(4
MX3^W^[86^]8>HC7:C(/^\?G)J5R P_/__P[I8 Z]'X+I_#6,<6W#!-_E9;.F
MPVKEHO7J_X!7?X;ISO^.DN2F=><?WYU?NU&A>/! 1$9:^7A4!W[MAO4N24?8
MD_L^"D*T_8>SJRBGYACO;3!#ZO1ZF9$RC ?)@>^WU6N@\O]9+ETK4J]__A%N
M "S*UF67_W+N@6]7I_#896R[;?%:4_78\Y6?:.O+[J6^;(VJRQZLU_X;Z+:W
M;\X.W@\./W\8=#N[3W+\3WCIZP9MR3OV'SQ3,E^C:/%T_>P%BR+5VH 0Y-3O
MY+#M40K=^KH]%$M'DR:I4=!J@?%0RO_:A](9Y=-8]PT3F;4?]%&:30EMQ;1N
M'*=P<T1/;S9/TH!M54PK)'<5DLVN2K;JWRPK],^7J^W>;\W?409.TST6'NAQ
M_G2_975GP2S( JEUBL+S:'SI#6?C!TN^W,LF?@>!L(=-?:S=KIRG:UO%$\P*
MQ'7F,I[B/Q<(\Q.J+&:Z_6#E7VNW9VMZDOI8D($]S")1__SA_[SZ\>6KU_]J
M-VJ]-NH[5WEGB]'OT;A85[VG'4(>C?(*O]/-:H_0.NX*8J*O7_)07S@^#V=O
M9V_%'?20:<,G"'OQ0!/Y$(0QTD]C<_,[> 7!J3P&=T.[0TUWDF#N:)P<YN(@
M("Z^316VDD6$IU'(5,]\*36L&]S957:\9-\+O//H*U&;,7P70O_T\"D.:)[T
MQ9<@\[:$%Y-=B'KOH><R4F _?>4I5'8<>D?1*%L@5\W><Q^5RK[O].1CAS\A
MB_U[8;BQ+)J>/$H2;S''%=+JJ$24I5%N$:4XG3$$IH^DGQX2%4;>?^UL[^SL
M(@0G8@=D$:Q/ 4N$0*+3Q13EXTM4(#X04_'^EWF1^0HR%V4*S+. #<>_Q2F"
M%X!P$?CQ/^'EQ27.&ZF?X2/_HCT6\NCJ7S<6@6!%MK^%JFFS_4\\V]_F%#<N
MIVC*%O:>WO@W(4'49A%;(5DI)&L^VK=D4T>SG$SN3:%*V11'K-4XZ[ +&RM.
M3W *Y\@VI%QQQM6;!S<J',$ N(BP&^3@N1(0GT,4>0>22,3[]8(I\JE[X HB
M9T[J[6_O_%]QYKN=X (^>X&MRA=9FB/$;SJ.HC GBNSE[]T$3WJ9R;_"H=YO
M'>K6H=XDA_H;M*5L0A?-^EN_QHG>;YWHUHE^=).V%9(GZ41SV0:V1F;(S72O
MJH0%E>91,I V0GH>X.K\GG7,HTK/!I^!%1[.\];#:3V<UL-9CYSA4Q[[MVU'
M/(WF690C+RQ5W&"AGW> (CMA^HM/5GCLC"FKO)>]9.M)SOHQZ>#WGJ-"O_=(
M*%.<P'NCD*N40J12P&@E[*#P\$9(_0W__N</HT62O/Z7CP')/U:$Y51@6=57
MQ#0NA5%C$I\;C,(2I^,XF ?CN& R$R1YCRZ#9%*JB')IY^ ]KK!]?J,^7RHJ
M*]=L=3NJ:*L\\-(7G0DT<J\LJ2CSI?"+ \^C*"_4$+_,TNLD"A'Z2'YC[=(C
MU#G>O^@]5D+D_F?2B[>Z'3A)7N8H0JYUO ZR# 1 N*IMV0#9MF3TQR4"2L2)
M1;:(Z(E"583'@$@,'<#3;D?($#4-8AY,B>AHS-^.B)\;OQ5/O.@K#CB'TSX-
MPJC^B1X_T$=V[0AV@_F*TGS5=)%A"60[GX-)A39H!&_A)P?XRS'>#OP"^A[1
M=5]'=1/E;Y$>P,^_]OXV?*-8E! JR,=?7*;7T15B->//_&:B/G;'R#6>UIX$
M29X:?EFC\X0,,8SS<9+FBRQ2K(XADBK>B2'6(L'%EQNZR-<TFDTX 9MTEM5A
MUJ6Z=)=-YTFLR$516#3EEE0TPT[G?%DFB5W0#-L?PV?F058(V^D\RI!RF 7)
M?,_-(8H*Z'8L'5 (G6>:J<]8Q_,1<H&M&"UK1)W'!;SS/U$(>I *WQ<Y[#)N
M%J@(10P;1I-X1I(B.N@RN&)B6Z2WCF<7N7<17Z%-(4SN_*CZVOA6!/[$3.X9
MH._[@H&X[?,>JLEO33"UGQKEUG>V/>NZ#=\O\]E#(UI_6WJTV__ONDKBFDK?
M?0[KMA16ZPFCWHK/8T/AW);3ZNG)SZ;!8Z_(M;YH<ZUMKK7-M:Y*?[59UH?N
M*OW\9O#U,A[%1;?35V@#3VL63[)X\.V;3U$V1<*XL-LYRJ+(^S6+"X0T, '\
MI[<53[E:XCB=10\1XWQL2^3'U][)G+('/WL?@KQH#9,',$R> C_"!H@^J)V3
MP]_0J?CK^_./'][\+U!+ P04    " "S@EA69>*P!F<#  #)$   "@   &5X
M,C,M,2YH=&WM6&V/FS@0_H[$?YA&NM6=%/)ZVP\)C40"Z:)C"0JTVWYTP"2^
M(YC:IKOIK^\ H=E66YU.VMUNI(L4P![/^'GF&9L7\RJZ]F:Z9EXYEHUGJ'YF
MY$:>,S/[S1FM_:/9G*_LCQ!&'SWG32?EN9K <% HB-B>2O#I+:SYGN3=IJ,+
M(14L[: CN@;_U6\*>R*V+)] -?3;?PJ*WBF#9&R+IICFBHK.S%RN_.C^#$9*
M]BP[3/YMCGJL9%]H ZDSN\@WLIB:_2H@YB!X2O2";7?J,<&;\YGSX<J=NY&N
MC<:]H=F?SYZ'RN,+@5Q:+<Z:Q&+EAXZ/@JR6X/JV$SAXP/!KYZT;1L[:L2%X
M-_?<!5B+Q>J='[G^6UBZZ^LSY_W<XOU=2L72PV.RN*&ZMJ.";@X0\UQBED!Q
M4#L*+(^Y*+@@BO$<T"YHB@/SN#+5(]9TRZ0Z#@@5472/_A*PM>1B#Z$QAM^7
M+*/@\QZ,QV-C=#E\?3GZHPLD3^H0@>"RH+$JI:Z%95%D=8@:BF*J5"S? H&"
M" 4\10\F?S)K9>:E0) (64&"W0E<$Q'O8#SHPF@P&G71F)$ZY)%B-0W/6#,X
M93G)8T8R79/WN*00DIP( M<TB2B&<_.X5^-G:);E1K*$$<$PZZ0H*%YA_&."
M, )3APLA/Y5\*L'*\Y)D2*"&V&9I.##^0EU$[7'  .B6T$37;!K3_88*& ]K
M L/>V5;9<]YQGFB1D$SR'Y?(:45@1RFA1.$:'6-2U/5YD265]LY=0862%Z)N
MM>5Q*GXXU?[_(O\B^*8[Z\N^KMU0\AE5K%9XQ));FF5=\'I>+T!EW//=Z)]6
MG4==;8[UWEGKFN7;$+GVC>-Y)P5>/GRKTB[OZEI$[XC\*>('Y&Z"O1 :2[H1
M)1$'?,K^L[[]C,\A^0]6.6)]91BP9#1+)A"0+9UB@$]EM7.CXQ16]68M)^ 1
MJ< PCJ^)INV^;U$UR(T-5XKO)_"Z4%/8<('[_;>^>4;B?V#8NT12]6,%$HNL
MN>?  DLXL&P;'WO?= :=NAT&UJ)M'^<XQHMYEI%"(K3V:@JW+%&[BN3@MX>V
MKFC=QL"M2[&89&UI*5Y\O[5D-*T][-;C7NA3_B*[>CE>5X>* 9XQ%VU:[B6S
M7V6SR=@Y5<2+1/HCQG[U*:+Y-E%]PO@*4$L#!!0    ( +."6%9U;%OB? D
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M[%EXW$K8PJTL'R2$R31* JW=?1.B,?C4'(*'N4ZE&7N'#K272RD?;\ ="J&
M:CQ"X\$CFD40!,$X&C[4@CD^"TRBNH^@V.<0\CIV/I:0ZAP7+%66D48SX=2:
M3!FA._@O^"F7<E-'P^@5X;.1YSID* YTG!0):B32'"NEB -BB7#.P(3<YIHT
M'^ 5"T$S=AK&S,/-Y ,'] ZW<Q=N\Z3G\1GBD.IH.L:$IPLTOH;H%W-G -ME
M=AT^SUAR);+S$#?M/IQ_HG#N.TL5J"LN,GB@F0$O<CI+)+QB7B$LED N==*%
MVR&ILW>%KU.TP/^,1 TG8N\E!6D\"QCO._4Y51?*%,(^RQA/7$,16II8NI;L
MWG5^(M>A.@C97?FB"F@C1@K5H[<WT.3](@03_&6NP*VRC\!=GRC\M7,Q?U'X
M2B3\V-4E/W7 E^L%PCRTKRX797PZ*P1CY*@SH5UCCRR LL55J/,MJ<N%5'6Q
M<#V7@$?TRVC!90S$]WUS%7DHP57&9>SK&95"."II!HE8GW]^_S%E?W?O^)#M
M'QX?]TYV]X]>OWA6:5;<]<GNP4&X_F;VBF/95K/Y^S8;0*-"UR*5)#PS\(SP
MK>+>M.CV3\,"9Y0[(IX$IB%>I7@;H]L_"*,*>MJ? ^\E//K 6N )W9&,9VL_
M;O[N3OY?\FE:=!A[2J6BRB";?P6@?W"5^#?+N.G66:,)"[FNL>HZ8[.]T=[P
M"G@KJ?&;TD%=F@OV-W.G7NQ)LXGO!R@!N/$G1YUVZ^DE]W7JNY/2][<\]^W6
MX_IFIU7O-)VT8^<O W*5>J0F:Q1V"8[K&PYI0=AY(OZ<^GAHN*#<N25@2,1P
MK6I=G</^4ZNQYU(D\18[X2.QC>D?<P&8Q;1M]L8#^18MTROV56NUH/"#H[>!
MLR5A-DF8 @["O0(/ZIV "!!NCG*+J+:,>I?AY2I<+<':U1=8/@MD*[4^QYVK
M6'UIN;E>@ZL$-^DVH)\5JAIHP3_4!H)2[A8R$2E]T3DV/<O_%LTL.&"#/-#[
MU_V;7_=O?MVI-[]N9>,&1?1@ZIHS*I%7[/JBXPO=(.UIIV$'=NFD;'9DM9]K
M3:1.188R?798_$?M?S1C((HSX5G%O7C8ZS=*W>W<N))>Y9JE?"+"3NW"IFDX
MI1(LXBZGA&W38S'B"7OEMW'JQ68I[<6,Y)D_09 F2.S:AUBY#I7']/X2]0WE
M4M%4$)?%RK2+-:*ZB7:J0)B:D?.Q,F*F/%#5R'22#I<]<R&_/9DUR/,3[UWT
M0KC;>KJQ45TX+9AOH>@\">^.H)'*DZ(?<IM1COR_X>#JY^I9OGZ!K^MNOIGA
MSE(.7!/%MX+.7-DZ?BS<=LJFB%M37:IU?[P>;]!?O\\8M[O7=&^5VV:K81J>
MCVMV*.X-\].P=6^ 6V7+!X1GY6NBXG8W3&ZIF?O2MDE[8=ODF!M[OV%RY[8%
M"IE"7=N@_RKT_V9(_XWX#U!+ P04    " "S@EA6NIQ%;0@8  "%M@  "P
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M_-GNM#]30ILG6'BQW-TT]3N@"JA$P1(CE269_":PY/6FSX].ZCW..H&_%^5
MGLDW);NO>W_E[M!W*799SC&^RW(9"7_^\=[IZY#RNF..D%;S/=&WJLDU;S&Q
M1Z3X)D-SN$>:!_++96'[[:6\<DV]'5+"+-NQ#\/#'V;CJ'M5^WBAYVN=X0_M
M[-/UZ='[X4F+-X\;WRPF*D/>^FI>F=>E[<'YYNCSM_Z[^L_S [M]^I4WK28]
M\JZ_'_";[>''(_>#./KB?#3T;>ZX_^WZ95'X;TV8/V_JXL>7+\Z6>[!]^\%C
MW6]#O?WMO34<V@>;GVOZ<?U\>'OXPSTM71Q4CK:[9[?^S4[__.+4HEQ<]3XW
MOWXZ?E<\?EL_VKK2SX?M4?N[>ZT[W<WFA3@\<SYT-YV\]K;0S-?/#IOM_!7O
M]'K-0K%7OMIL;%^UZ\7V1;[][LHKZO5K[^OW;]\+^G^WCX=<:WURWBAT_#]0
M2P,$%     @ LX)85J* VU11 P  R P  !$   !S;71I+3(P,C,P,C(T+GAS
M9+56VW+:,!!];F?Z#ZK?A6UH+A!(IDU*AQEH,R&WZ4M'V MH8DM&DH'DZROY
M N9:3%L_2:MSSNY*NY*;5_,P0%,0DG+6LMR*8R%@'O<I&[6LAS[^W+_N="QT
M=?GA/=)?\R/&J$TA\!OHAGNXPX;\ GTG(330-V @B.+B CV2(#86WJ8!"'3-
MPR@ !7HA]=1 )Q7W;( P/D#W$9C/Q<-=9Z$[5BJ2#=N>S685QJ=DQL6+K'@\
M/$RPKXB*Y4+-F3O9=QB]1Z6W(-=/>Y$\F]_1YQ&P\_B&L)E\(OVO,+BMOYW\
M/)_ RWCZ]*4V> Q/WUYE-/7K':]OSQ5SGAZ@UTY=-J4WAI @?1A,MBR37Y;>
MK%;A8F17'<>UGWO=?H*S4F!C'E#VL@WNUNMU.UG-H1O(^4 $N73--LL#(F&A
MK%?I'CQE4A'FK>!]M2 4P2=VNK@"I5NAIRF4YE ?UG 2O,J(3VV]H/'5:@Z,
M)1X1$BW 0R('B:@4"LLX2L"36@[7UJW0%4U#5:\1R.VJR=(*H=^[[RRPDC B
M=+GX"KRQ*4T#K6GT)]U@ 83 5)N+\ :&) YT-).8!'1(P;>0(F($RM2:C(@'
MATCF54L8X[JX=8=E%F.+(JJK5QO>-<TQ-P0/X%Y'C\Q M]4>!P9A7W-]/UB(
M^BTK'1HI+9R(^3"DC"8>LR9R$38M$YL4]3"A-.UU<$$BEN#_8)?).!(@-2])
MH:L-&3&#["!Y)/#BH!QG&<I62F;(MVJY>7FCW,$0)0W6,(70LB0U5YR5V<8"
MAMH6*HKS,_JE4ZOH0LDA1GI/@R4[O[X;F>-<@@AO0V7C M B/ *AJ*[60I>G
MH5-EZ+<%-\CXD1:R_T7* 1F435E3(/B/N7:-?C')K$OL99MD\_56:NITN5"(
M;33FONLQO=B[W$ND]E#,#.<\;$S8K>*:6YE+?QEIF2"6.U NB)QW1! [+NEM
M_N4NN!F8$JH>ZG1Q+6>OP"%.MW)L")3,+7\5PLJ;4SZ02:THA%-3Z5C6W[[#
MXLB?01U#)G"L?YU"\9'\B_-(9$H=R$II^TK81L*(.MAQ<=7='<Z?F,E<'M40
M'H^9$J]EFJ)(R2?'5>;R]Z9<':2'8$KA6+='5,&F\VTET+13-3W\#5!+ P04
M    " "S@EA6HIOKK/X*  " A@  %0   '-M=&DM,C R,S R,C1?;&%B+GAM
M;,V=76_CN!6&[POT/[#N30N,XXF#;9'L9!<93[(P-INDL6>V[:)8T!+C")')
M@)(3^]^7%$59HG@D)45)SL6,1WP/]5)\3%)?QY]^W&U2]$)XEC!Z/CH^^CA"
MA$8L3NCZ?/1U,;Y8S.;S$<IR3&.<,DK.1Y2-?OSACW] XL^G/XW'Z"HA:7R&
MOK!H/*</['MT@S?D#/U$*.$X9_Q[] VG6[F%724IX6C&-L\IR8DH4#L^0]\=
M'?]]A<;C ?5^(S1F_.O]O*KW,<^?L[/)Y/7U]8BR%_S*^%-V%+'-L H7.<ZW
M657;Q]W'\H\*_Y0F].E,_K7"&4'B>-'L;)<EYR.YWW*WKR='C*\GTX\?CR?_
M_.5Z$3V2#1XG5!ZWB(QTE*S%%G=\>GHZ*4JUM*7<K7BJ]W$RT7:JFD5ITJ&O
M.<F2LZRP=\TBG!?=WKL;!"KD_\9:-I:;QL?3\<GQT2Z+1_K@%T>0LY3<DP=4
M-/,LWS\+E+)$DC JMSUR\F WDW(^D?$32M8X)['<T:G<T?'?Y([^7&Z^QBN2
MCI!4"C[ =ITVZBJ#)J[-WA&>L/B2OL^U&>W)OOCN\/Q_:$ ]WGD3EBS'Z;O,
MUR.=V[XA[SOBASCW1UJ,\^1]1[H6^7^QG;<MO_GPVH]K*C=>BT\-BV27BPF,
MQ-JDK*)C!"[V4$P,9=U5[2QJU)O*T9SQ=MOES%C4F9'H:,U>)C%)1-W3J?PP
MEA^*9HO__#YC8B5PL<IRCJ-<UU0TXWQD*9^8EJ3R@FM?F$<]C2L5DXB)J>DY
M'Z?J,*KP!\XVUMV6K6:6PM_3516O#HO8!6"T(>,D8UL>D3?U2MTM=)1*1YM4
M*.22BM#QU\7HAT*#?M.J_WR:'&IQT-%B";3=$)HO18V6%C2+776SS93NY7I9
M$)UL,63VL98@J7'<P1=BQ['<^56*UQ;[1KFK+K;:TGW<* RBDVV.S%ZN-$B*
M?'7S%Y)%/'F6R_FN=C1DSCO=8K+5]S5-6 BTC<$DU+2>!O9[LD[DU"(MR/-;
M(C=V#&. WO70WVG;G NLXB"@&>(0G"WJ0:B*\L31!:5;G-Z39\:[\&G*7%-C
M,VG"4M<$Q8C%&(B&TB(E]D3$/[;BC)WP=-\+14OIF@O JHF&(0N*#KLW$)!*
M[I>1)<<T2^0 U@M)6^K\= ,PVSKU,'1!<0*8@T])*KU?4A:/)$WE_0!,^P<4
MF]@U+;!ADY>V,BAB0'L@,T4$*D/"P>;R1:[.Q3)I8&-K>I_PM&QW\5.)@T7(
M=#B0HB(,R3A/)-5N0_0PU%*ZI@>P:G)CR((BQNX-9$7)4:'W#\DEC0<A4NG\
M &+8M.-1B@*$H^FL#PVA]@G&59)%.%5>KL2VK*-Y%JUK0$"[)B0M85"@0.Y
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MF?KHK$E(CZ/;H&P3S="\M.TGSH<!)]-JG'LF0)Y=#*"5:K"(?J0Z5FSNN-2
MW;$$\NVA\JW0UC#F\MQYH%/F_'6NN LO=0?#XX*G"!#\">9($52+%(%+(3+"
M'^A<JAKPNY9 WF\P>5=I0\+\=T:4H8JO(*0/C(&PWV+"]BA$XOVHB-#,\8$
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M4$L! A0#%     @ LX)85G5L6^)\"0  E#@   D              ( ![<
M &5X-2TQ+FAT;5!+ 0(4 Q0    ( +."6%:ZG$5M"!@  (6V   +
M      "  9#*  !F;W)M."UK+FAT;5!+ 0(4 Q0    ( +."6%:B@-M440,
M ,@,   1              "  <'B  !S;71I+3(P,C,P,C(T+GAS9%!+ 0(4
M Q0    ( +."6%:BF^NL_@H  ("&   5              "  4'F  !S;71I
M+3(P,C,P,C(T7VQA8BYX;6Q02P$"% ,4    " "S@EA6=,YR 5L'  #?5P
M%0              @ %R\0  <VUT:2TR,#(S,#(R-%]P<F4N>&UL4$L%!@
0   '  < I $   #Y      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
